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Design of a high-quality vaccine requires more than just initiation of a robust 
immune response, as there are several other factors that should be considered during 
development. An ideal vaccine should be efficacious and cost-effective, with minimal 
side effects and reactogenicity. Additionally, it is important to consider required number 
of doses and storage requirements.  
Streptococcus pneumoniae is the major causative agent of bacterial pneumonia, a 
debilitating disease and the leading cause of death in children under the age of five 
worldwide. There are several existing vaccines against S. pneumoniae, though none are 
protective across all serotypes. Pneumococcal surface protein A (PspA), a key virulence 
factor of S. pneumoniae, shows promise as a target antigen for future vaccines, to address 
challenges presented by diversity of the capsular antigens.  
Yersinia pestis, the causative agent of bubonic, septicemic, and pneumonic 
plague, induces a highly lethal infection if left untreated. There are no currently existing 
licensed vaccines against Y. pestis. New research using the recombinant fusion protein 
F1-V, in vaccine formulations against pneumonic plague, have shown protection across 
several species.  
Biodegradable polyanhydrides have been studied as a nanoparticle-based vaccine 
(i.e., nanovaccine) platform for stabilization of labile proteins and enhanced shelf storage. 
Nanovaccines have also been shown to have inherent adjuvanticity and induce humoral 
and cell-mediated immune responses. The STimulator of INterferon Genes (STING) 
agonists cyclic dinucleotides (CDNs) have been shown to be promising next-generation 
adjuvants capable of initiating rapid, protective humoral responses.  
x 
Vaccine formulations, described herein, were comprised of either polyanhydride 
nanoparticles alone or in conjunction with the CDN R,R-CDG, against Y. pestis or S. 
pneumoniae. Immunization with a single-dose of these nanovaccine formulations, 
induced protective immunity against lethal challenge at both early (14 days post-
immunization) and late (180 days post-immunization) time points, and maintained 
efficacy following shelf-storage at 25˚C for 60 days. The ability of these vaccine 
formulations to be efficacious following a single immunization, induce rapid and durable 
protective humoral responses, and maintain potency after shelf storage, highlight the 
potential of polyanhydride nanoparticles as a promising next-generation adjuvant and 
vaccine delivery platform.  
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CHAPTER 1.    LITERATURE REVIEW 
The introduction of vaccination, as a strategy against infectious disease, is largely 
considered one of the most influential developments in medicine. Vaccination has been 
responsible for the reduction in prevalence of diseases that were once the cause of severe 
morbidity and mortality worldwide (e.g., rinderpest, smallpox, polio). Beginning with the 
first observations of Edward Jenner in the 18th century, that inoculation with the cowpox 
variant of Variola virus conferred protection against smallpox, and leading to the 
development of what would be the strategy of live-attenuated vaccination, vaccines 
remain, to date, the most efficacious form of preventative medicine1.   
New discoveries over the past decades have led to the development of many new 
antigens, adjuvants, and delivery platforms that allow modern-day scientists to further 
develop novel vaccination strategies. Coupled with furthered understanding of the 
immune system and pathogenesis of disease, we are better equipped now more than ever 
to design next-generation vaccines against infectious diseases.  
Rational Vaccine Design 
Designing a high-quality vaccine is about more than just initiating an immune 
response, as there are several other factors that should or need to be considered during 
development. An ideal vaccine should be efficacious and cost-effective, with minimal 
side effects and reactogenicity. Additionally, it is important to consider ease of 
administration, required number of doses, route of immunization, age and health status of 
immunized individuals, and storage requirements.  
Storage of vaccine doses is of major concern in the health care community, as it is 
can be difficult to maintain cold storage and many existing vaccines are exposed to 
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temperatures, either above or below recommended temperature range, which may impact 
their potency2,3. Cold-chain storage of vaccines is so hindering, that many companies 
have started to develop solar-powered refrigerators for use in the field and in developing 
countries4. Development of shelf-stable vaccines would be beneficial both for global 
dissemination and reducing cost associated with storage.  
Patient compliance can also be an obstacle to overcome when attempting to 
achieve proper herd immunity, as many individuals do not return for booster 
immunizations or the trained health care personnel are not available5,6. From this 
standpoint, design of single-dose efficacious vaccines is imperative. In addition to 
increasing percent of compliance, administering a single dose can also help to 
significantly reduce costs associated with vaccination, and allow for production of more 
doses, which is of extreme importance in the event of an outbreak. In addition to these 
concerns, single-dose immunization strategies may also confer better overall protection, 
particularly against those pathogens whose primary correlate of protection is opsonizing 
antibody. It has recently been demonstrated that repeat immunizations of human subjects 
can cause further class-switching of IgG1 to IgG4, which is known to be a poor opsonin7.  
Route of immunization may also play a key role in the efficacy of a vaccine. 
While oral immunization induces the production of local antigen-specific IgA and IgM, it 
has been recently reported that subcutaneous vaccination routes lead to the presence of 
higher levels of IgG systemically, as well as in the lungs8,9. Additionally, recombinant 
protein and inactivated/killed mucosal vaccines have been shown to be poor activators of 
cell-mediated immunity, showing decreased CD8+ T cell activation and proliferation as 
compared to systemic immunizations10. Therefore, when considering the rational design 
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of a vaccine against respiratory pathogens, it is important to consider that route of 
immunization could play a key role in conferring overall protection, especially for those 
pathogens where the correlate of protection is opsonizing antibody.  
Adjuvants: An Immunologist’s Secret Weapon 
Unlike many live-attenuated vaccines, those based on the use of subunit proteins, 
such as recombinant F1-V, are poorly immunogenic when administered alone11.  In order 
to initiate a protective immune response to a vaccine, researchers must consider the 
incorporation of adjuvants into these formulations. Adjuvants are substances designed to 
enhance the body’s immune response to a given immunogen. Commonly used in vaccine 
formulations, they serve to improve efficacy through the induction of inflammation and 
pathogen-mimicking signals, helping to initiate an immune response to the target 
antigen12. They can also serve to better enhance delivery or stability of a vaccine 
formulation. The ideal adjuvant is inflammatory enough to initiate a proper immune 
response, without causing overt inflammation and administration-site tissue 




One of the oldest and most widely-used adjuvants in vaccine development is 
aluminum salts (alum). First discovered in the 1920’s, aluminum salt-based vaccine 
adjuvants are the most prevalently used adjuvants in currently licensed vaccines14. 
Antigens administered with alum are adsorbed to the adjuvant through anionic ligand 
exchange and electrostatic attraction, which may impact how antigens are seen by antigen 
presenting cells (APCs), specifically dendritic cells (DCs), in the early adaptive 
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response15–17. Vaccines adjuvanted with alum include formulations against: diphtheria, 
tetanus, pertussis, hepatitis A, hepatitis B, influenza, and pneumococcal pneumonia11. 
These adjuvants have been shown to be strong initiators of Th2 immune responses, 
characterized by abundant antibody production, with little to no activation of cellular 
immune responses18. Current mechanism of action is not fully elucidated, but there have 
been numerous publications indicating that depot formation at the site of immunization 
created by alum leads to prolonged inflammatory signals that also contribute to the 
magnitude on the resulting immune response18,19.  
AS04 
Another FDA-approved adjuvant, currently used in the Ceravarix® vaccine, 
Adjuvant System 04 (AS04) is the first combination adjuvant to be approved for use in 
the United States. Comprised of monophosphoryl lipid A (MPLA) and alum, AS04 has 
been shown to confer better cell-mediated immunity than formulations adjuvanted with 
alum alone, generating protective memory cytotoxic T cells in addition to long-lasting 
antigen-specific antibody11,20. MPLA is isolated from a deep rough mutant of Salmonella 
minnesota, and has been shown to have adjuvant properties similar to lipopolysaccharide 
(LPS) as it relates to the stimulation of host cells through TLR4 in a pathogen-mimicking 
manner21. Combination of these two adjuvants (alum and MPLA) has been shown to 
increase the overall magnitude of the antigen-specific antibody titers, as compared to 
either component alone23.  
MF59 
MF59, an oil-in-water emulsion comprised of squalene droplets in aqueous 
solution, has been approved for use in the United States since 2015 as the adjuvant in 
Fluad® seasonal influenza vaccine11. MF59 has been touted as a strong inducer of both 
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humoral and cellular immune responses, particularly in the elderly population22. Though 
the complete mechanism of action surrounding MF59 is still being fully elucidated, 
several studies have shown the production of pro-inflammatory cytokines (i.e. IL-2 and 
IFN-γ)  at the site of immunization, which led to the differentiation of DCs and have been 
shown to prolong germinal center persistence post-immunization22–24. While the last 30 
years have yielded few new potent adjuvants (e.g., MPLA, AS04), further research is 
warranted to identify promising next-generation adjuvants.  
Next-Generation Adjuvants 
Cyclic dinucleotides 
Cyclic dinucleotides (CDNs) are a novel class of adjuvants comprised of small 
molecules that act as second messengers. CDNs can be host-produced or bacterial in 
origin, signaling through STING (TMEM173) pathway, upstream of nuclear factor-κB 
(NFκB) and interferon regulatory factor 3/7 (IRF-3/7)25–27. STING is a transmembrane 
protein located on the endoplasmic reticulum, which dimerizes and translocates to the 
perinuclear Golgi region after interaction with cytosolic DNA bound to cyclic GMP-
AMP synthase (cGAS) or dsDNA, recruiting TANK-binding kinase 1 (TBK-1), which 
phosphorylates STING and IRF-326,28.   
Activation of STING by pathogen-secreted CDNs or host cytosolic DNA leads to 
the expression of type I interferons (IFNs) and pro-inflammatory cytokines highlighting 
the potential for CDNs as a potent immune activator29,30. Type I IFNs have been 
associated with increased antigen persistence within DCs by reducing endosomal and 
lysosomal acidification rates31. Type I IFNs have also been associated with the 
broadening of TCR specificity, augmenting proteasome peptidase activity allowing for a 
differential array of peptides to be presented on MHC I32.  STING pathway signaling can 
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be initiated with host DNA that is the product of naturally-occurring DNA damage, 
leading to the production of type I IFNs that may serve to prime innate immunity for 
rapid responses to new pathogens25,33.  
Of known CDNs, cyclic di-GMP (CDG) is the most common, produced by most 
gram-negative bacteria, and has been of interest as a potential vaccine adjuvant. 
Administration of CDG as part of a vaccine formulation  has been shown to induce 
balanced humoral immune responses, characterized by equal production of IgG1 and 
IgG234. Additionally, it also activates cellular immune responses, leading to the 
production of IL-2, IL-4, IL-6, IL-12p40, IFN-γ, TNF-α, and increased lymphocytic 
proliferation34,35. Studies evaluating CDG as a potential adjuvant have largely focused on 
the induction of cell-mediated immunity and shown it to be a potent stimulator of 
cytotoxic T cell proliferation29. The ability of CDNs to facilitate the induction of both 
humoral and cellular immunity supports to inclusion of CDNs as a potent 
immunostimulatory adjuvant in vaccine formulations.  
Polymer-based adjuvants 
Biodegradable polymer-based vaccines are on the forefront of next-generation 
adjuvant and vaccine delivery platform technologies. Polymer-based biomaterials have 
been extensively studied as drug delivery platforms and biodegradable devices with 
surgical applications, but also show promise as potential adjuvants due to their 
biocompatible degradation products, potential ability to stabilize labile antigens, 
prolonged and customizable release kinetics, and their breadth of storage capabilities.  Of 
the many researched polymer classes, the two that remain the most promising in potential 




Poly(lactic-co-glycolic acid) (PLGA) is the most successful polyester-based 
biodegradable polymer that has been studied to date. Upon hydrolysis, PLGA breaks 
down into easily metabolized monomers of lactic and glycolic acid and has a generally 
low phlogistic profile36. Current licensed applications of PLGA include biodegradable 
surgical sutures and microparticle drug delivery products37.  PLGA can be fabricated into 
either micro- or nanoparticles containing antigen and are being extensively studied as 
vaccine delivery platforms38.  
 PLGA particles exhibit bulk-eroding degradation characteristics wherein water 
easily penetrates the polymer, sometimes resulting in quick release of the antigenic 
payload, and have a glass transition temperature (Tg) of 37˚C, making them very glassy 
and rigid at ambient temperatures36,39.  PLGA-based nano- and microparticle vaccines 
have been associated with Th1 immune responses and the production of IFN-γ, IL-12p40 
and antigen-specific IgG240–42.  Recent studies have shown that a single vaccination with 
PLGA microspheres containing tetanus toxoid initiated a comparable humoral immune 
response as a multiple-dose formulation of antigen adsorbed to alum43. PLGA is an 
appealing potential vaccine delivery candidate due to its history of FDA-approval, 
biocompatible degradation products, and ability to induce both humoral and cellular 
immune responses.   
Polyanhydrides 
Polyanhydride-based polymers have also been recently researched as potential 
vaccine candidates, with some polymers already being used in the FDA-approved drug 
delivery product Gliadel® wafer, composed of 1,3-bis-(p-carboxyphenoxy)propane and 
sebacic acid44. Comprised of varying ratios of sebacic acid (SA), 1,6-bis(p-
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carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG), the resultant co-polymers are biodegradable and have biocompatible 
dicarboxylic acid breakdown products and degrade through surface erosion45. Each 
individual polymer exhibits different degradation rates, with CPTEG exhibiting the 
highest rate of erosion, followed by sebacic acid at days to weeks before full degradation, 
with CPH having the slowest rate at months to possibly years45. Due to these varying 
erosion rates, altering the ratios of each monomer in the polymer formation allows for 
tailoring of the payload release kinetics46.   
Following release, polyanhydride polymers have been shown to confer protein 
stability, conserving the functional activity of encapsulated proteins for up to four 
months47. Additionally, polyanhydride-based nanovaccines have been shown to maintain 
efficacy and induce protective immunity following storage at room temperature for two 
months48.  Immunization with polyanhydride nanoparticles has demonstrated lower levels 
of administration site reactogenicity and inflammation as compared to more traditional 
adjuvants, such as alum and Freund’s Incomplete Adjuvant49.   
Polyanhydride nanovaccines have shown to initiate protective immunity against a 
wide variety of bacterial and viral pathogens including Streptococcus pneumoniae, 
Yersinia pestis, BRSV, and influenza virus48,50–53. These formulations have also been 
shown to exhibit inherent adjuvanticity, capable of enhancing both cellular and humoral 
immunity, and contribute to dose-sparing capacity making them very promising 
adjuvants for expensive subunit protein vaccines48,50,51,54. Due to their characteristics of 
tailored payload release kinetics, protein shelf stability, adjuvanticity, biocompatibility, 
low injection reactogenicity, dose-sparing capabilities, and ability to induce protective 
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immunity following a single immunization, polyanhydride-based nanovaccines remain a 
promising next-generation vaccine delivery platform49,55,56. 
Bacterial Respiratory Diseases and Prevention Strategies 
Respiratory Infections 
The mucosal surface of the respiratory tract is one of the body’s first lines of 
defense against infectious disease pathogens. Disease tolerance of the respiratory tract is 
mediated through physical barriers, innate immune activation, and the adaptive immune 
response. Physical barriers of defense are mediated by the production of mucus secreted 
by goblet cells, continual propelling of mucus by ciliated cells, club cells, and basal 
cells57,58. Cellular innate immunity in the respiratory tract is primarily mediated by 
alveolar macrophages and neutrophils, which rapidly produce type I interferons, 
antimicrobial peptides, and reactive oxygen species upon contact with pathogens, and 
secretion of naturally occurring antibody from innate-like B1a cells59–61. Components of 
adaptive immunity in the airway also include cytotoxic T cells, tissue resident memory T 
cells, and the local production of IgA and IgG62,63.  
Infections of the respiratory tract manifest as either upper respiratory infections, 
such as those caused by the common cold, or lower respiratory infections, such as 
bronchitis and pneumonia64. Pneumonia occurs when there is significant swelling of the 
airway and the alveoli fill with interstitial fluid or inflammatory cells, and can be 
bacterial, viral, or fungal in origin65. Community-acquired pneumonia is the leading 
cause of death from infectious disease worldwide, leading to hospitalization in over 45% 
of all cases65. Though community-acquired pneumonia can be the result of many 




Streptococcus pneumoniae is a gram-positive bacterium, which colonizes the 
mucosal surfaces of the upper respiratory tract and is one of the most common bacterial 
respiratory pathogens worldwide67. Septicemic pneumococcal infections account for 
approximately 25% of all deaths in children under the age of 568. Colonization of the 
nasopharyngeal tract typically occurs within the first 6 months of life, with approximately 
53% of children under the age of 6 being identified as carriers, as well as 4-11% of the 
adult population69,70. Streptococcus pneumoniae colonization is very common in healthy 
individuals and active infections occur primarily as the result of opportunistic infection 
following existing viral infection71,72. Other risk factors that have been associated with 
increased prevalence of infection include age (< 5 or > 65 years of age), primary or 
secondary immunodeficiencies, smoking, and colonization of a new serotype73. There are 
95 known serotypes of S. pneumoniae, characterized by variations in the capsular 
polysaccharide74.  Of the existing S. pneumoniae serotypes, 40 are known to be 
potentially pathogenic75.  
Protection from S. pneumoniae infection is conferred primarily through protective 
antibody76. During natural infection, B1a cells play a significant role in conferring 
protection by traveling from the pleural space to the parenchyma from the lung, where 
secretion of polyreactive IgM has been shown to provide protection against acute S. 
pneumoniae infection77. Complement activation has also been shown to play a central 
role in reducing bacterial replication following infection, highlighting the importance of 
the innate immune system in controlling early infection78.  
Current preventative strategies against S. pneumoniae include the use of PCV7, 
PCV13, and PPSV23 vaccines. PCV7 and PCV13 are both pneumococcal conjugate 
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vaccines (PCV), where capsular polysaccharide from either 7 or 13 serotypes is 
conjugated to a carrier protein (diphtheria CRM197 Protein)79. PPSV23 is a polyvalent 
pneumococcal vaccine containing purified capsular polysaccharides from 23 serotypes, 
with 57-75% efficacy against homologous serotypes79,80. All existing vaccines initiate a 
similar humoral immune response and have been shown to significantly reduce incidence 
and severity of pneumococcal infection81. Though these vaccines have been successful, 
there are still limitations, as they only confer protection across homologous serotypes76.  
Recent studies also have shown a shift in serotype prevalence in infectious cases towards 
those not included in the existing vaccines suggesting vaccination may be skewing 
infectious serotype prevalence73.  New vaccination strategies against S. pneumoniae 
include the use of the recombinant subunit protein pneumococcal surface protein A 
(PspA), which is found on most serotypes and plays a significant role in colonization and 
transmission82,83.  
S. pneumoniae has several key virulence factors including pneumolysin, two 
neuraminidases, and PspA. PspA a choline binding protein, is one of the most abundant 
proteins located on the pneumococcal cell surface, and plays a critical role in facilitating 
nasopharyngeal colonization through inhibiting host complement activation82. Unlike the 
large number of capsular polysaccharide types, there appears to be only six clades of 
PspA with the majority of strains in clades 1 and 2. Anti-PspA antibodies induced by 
immunization with a combination of PspA from clades 1 and 2 have been shown to be 
cross-protective against S. pneumoniae strains across all six clades of PspA, and provide 
protection against septic S. pneumoniae challenge when passively transferred to naïve 
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mice84–87. The ability of anti-PspA antibodies to provide protection across many 
serotypes of S. pneumoniae highlights its potential as a vaccine target.  
Yersinia pestis 
Yersinia pestis (Y. pestis), is a gram-negative, non-motile, facultative, 
intracellular, bacterium with a notorious reputation. As the causative agent of plague, Y. 
pestis has been responsible for over 200 million deaths historically including multiple 
pandemics often referred to as Justina’s plague and the ‘Black Death’ of the Middle 
Ages88. Plague is a disease primarily afflicting rodents, with humans serving as an 
incidental or dead-end host to Y. pestis89. In the human, there are three manifestations of 
plague infection: bubonic, septicemic, and pneumonic.  
Bubonic plague develops after an individual is bitten by an infected flea. The 
bacterium disseminates from the wound site to the draining lymph node where it 
undergoes rapid proliferation90. Following proliferation, the bacterium may disseminate 
systemically (i.e., septicemic plague) resulting in sepsis which may lead to septic shock 
and death90.  Y. pestis can be transmitted from an infected individual through inhalation 
of respiratory droplets leading to the development of pneumonic plague91. Pneumonic 
plague is the deadliest manifestation of Y. pestis infection, with mortality rates near 100% 
if left untreated92. There are currently no existing FDA-approved vaccines against Y. 
pestis, though recent research has led to some limited success with subunit vaccines (e.g., 
F1-V antigen), live-attenuated and live-vectored Y. pestis vaccines93. 
 Yersinia pestis is a highly lethal pathogen, partly due to its various 
mechanisms of immune evasion. Upon passage from the flea to human host, the 
temperature transition causes a shift in surface lipopolysaccharide from hexa-acylated to 
tetra-acylated, causing it to no longer be detectable by TLR4 preventing initiation of 
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innate immunity94. This transition in LPS and the presence of outer membrane protein Ail 
has also been shown to provide Y. pestis with resistance to complement-mediated 
killing95. Following infection, Y. pestis preferentially infects and proliferates insides host 
macrophages, evading the host’s immune system and allowing it time to upregulate 
Yersinia effector proteins (Yops)96. 
 There are currently six known Yop proteins, each serving a unique role 
and being critical to Y. pestis virulence and survival in the extracellular space (Table 1.1). 
Utilizing a type III secretion system (TTSS), Y. pestis, directly delivers Yops to the 
cytosol of target cells97.  LcrV is a key virulence factor of Y. pesits. Found at the tip of the 
TTSS, it is critical for forming a pore in the cell membrane to allow for the injection of 
Yops98. Y. pestis also expresses the capsule-like antigen fraction 1 (F1) in the human 
host, which acts as a virulence factor by inhibiting phagocytosis99.  
Currently, there is no FDA-approved vaccine against Y. pestis, making it critical 
to develop a protective vaccine for application in potential outbreak scenarios. Many 
vaccination strategies have focused on developing strong humoral immunity, 
characterized by neutralizing antibodies against the V antigen and opsonizing antibodies 
against the F1 capsule100–103. In mice, anti-F1 IgG antibodies have been shown to 
correlate with protection100. Additionally, mAb 7.3, which binds to the V antigen, has 
been shown to neutralize Y. pestis in vitro and provide protection against lethal challenge 




Table 1.1 List of known Yop proteins important for Yersinia pestis virulence 
 
The United States Army Medical Research Institute of Infectious Diseases 
(USAMRIID) developed a recombinant fusion protein F1-V, containing both full length 
proteins of both F1 and V, which has been of recent interest as a target antigen105. Using 
a prime-boost regimen, it was recently demonstrated that F1-V adjuvanted with alum 
provided complete protection against intranasal challenge with Y. pestis CO92 in mice, 
guinea pigs, and macaques, highlighting its potential as a protective immunogen in the 
development of vaccines against Y. pestis106.  
Trained Innate Immunity 
The innate immune system is the body’s first line of defense against invading 
microbial pathogens in a non-specific manner, through the ability to distinguish self from 
non-self. Innate immunity functions through the recognition of conserved pathogen-
Yop 
protein 
Function Mechanism of action 
YopE Anti-phagocytic 
Inactivates Rho family GTPases, hindering actin 
cytoskeleton rearrangement195 
YopH Anti-phagocytic 
Targets tyrosine-phosphorylated proteins, 
dephosphorylating (Fyn Binding protein) FyB 
and Src kinase-associated phosphoprotein 2 
(Skap2) in macrophages196–198 
YopM Inhibits inflammasome 
Restricts activation of pyrin inflammasome – 
mechanism largely unknown199 
YpkA Anti-phagocytic 
Inhibits Gαq signaling through phosphorylation 
of the α subunit200 
YopJ 
Apoptotic 
Inhibits NFκB signaling 
pathway 
Acts as a ubiquitin-like protease to initiate 
apoptosis201 
Blocks phosphorylation and activation of 
mitogen-activated family kinases and NFκB202 
YopT Anti-phagocytic  
Cleaves Rho protein, inactivating GTPases and 




associated features, such as microbial-associated molecular patterns (MAMPs) or danger-
associated molecular patterns (DAMPs) through pattern-recognition receptors (PRRs). 
There are five families of PRRs consisting of: Toll-like receptors (TLRs), C-type lectin 
receptors (CLRs), nucleotide-oligomerization domain (NOD)-like receptors (NLRs), 
RIG-I-like receptors (RLRs), and AIM2-like receptors107,108. The families of PRRs 
together allow for the recognition of microorganisms both extra- and intracellularly107.   
The recognition of MAMPs and DAMPs activates the innate immune system 
allowing it to respond quickly to foreign bodies and induce complement activation, 
inflammation, and recruitment of phagocytic cells. The cellular response associated with 
innate immunity is comprised primarily of monocytes, granulocytes, and dendritic cells, 
which facilitate the killing of microorganisms109. Additionally, activated macrophages 
contribute by inducing local inflammation, through the secretion of pro-inflammatory 
cytokines including TNFα, IFNγ, IL-1β, IL-6, IL-12 and IL-23110. This inflammatory 
response further attracts monocytes and neutrophils to the site of infection111. The 
combined efforts of the innate immune response are critically important for the control of 
infection in the first 24-48 hours post exposure. However, more recent data suggests that 
priming of the innate immune system by infection or vaccination could have longer 
lasting effects, up to three months, through the process of trained innate immunity112.  
Trained innate immunity exhibits adaptive characteristics, initiated through the 
process of epigenetic reprogramming in neutrophils, monocytes, and natural killer (NK) 
cells, that alters immune signaling pathways and cellular metabolism113. Such involved 
mechanisms of epigenetic reprogramming include histone modification, chromatin 
reconfiguration, and DNA methylation114. Increased responsiveness to stimulation is also 
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conferred through a metabolic shift from oxidative phosphorylation to aerobic glycolysis 
in monocytes, allowing for increased proliferative and cytokine production capacity114.  
Trained monocytes, with histone modifications, show significantly increased 
transcription of genes encoding IL-6 and TNFα, and ex vivo were found to have increased 
reactive oxygen species production for up to three weeks following non-specific 
challenge115,116. These mechanisms allow the innate immune responses to retain a certain 
degree of immunological memory, which can help to confer protection to secondary non-
related infections in a B and T cell-independent manner116.  
While mechanisms surrounding the development of trained innate immunity are 
still being fully elucidated, several transcription factors have been identified that may be 
crucial in determining epigenetic and transcriptional programming117. Other research 
indicates inhibiting synthesis of cyclic adenosine monophosphate (cAMP) or mTOR 
during the primary response eliminates the protective effect of trained innate immunity 
following secondary infection in human and murine models117,118.  
Humoral Immune Response 
The whole of the adaptive immune response can be organized into either cellular 
(i.e., cell-mediated) immunity or humoral immunity. Humoral immunity is responsible 
for immunity in the extracellular space and is primarily mediated by the production of 
and secretion of antibodies. Antibodies contribute to immunity through several 
mechanisms including marking pathogens for phagocytosis and elimination 
(opsonization), prevention of pathogen entrance into cells (neutralization), immune 
exclusion at mucosal surfaces, and complement activation via the classical pathway119.  
Opsonization (from Greek – prepare for eating) entails the coating of microbial 
surfaces with an opsonin, such as antibodies and complement C3b, enhancing phagocytic 
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uptake and playing a crucial role in the control of many diseases120. Phagocytic uptake 
via antibody-mediated opsonization is facilitated through the binding of the Fab portion 
to its cognate epitope on target pathogen surface and interaction with Fc receptors present 
on the phagocyte121.  Antigen-specific antibodies can also contribute to control of 
infection through the process of neutralization, by which antibodies can coat microbial 
surfaces, bind to pathogen ligands, inhibit virulence factors or toxins, and prevent further 
spread of pathogens by preventing fusion/entry into host cells119,122. Additionally, 
antibodies can activate the complement system by the classical pathway.  
There are three pathways upon which complement can be activated, the classical, 
lectin-mediated, and alternative pathways. The lectin pathway relies upon the recognition 
of MAMPs or DAMPs on the pathogen surface, by the pattern recognition molecules 
(PRMs) mannose-binding lectin (MBL), collectins (collectin-10, collectin-11), or ficolins 
(ficolin-1, ficolin-2, ficolin-3)123. The PRMs complex with the mannose-binding ligand-
associated serine proteases (MASPs)123,124. Upon binding of PRMs, MASP-2 can initiate 
cleavage of C4 and C2 complement components, forming the C3 convertase C4bC2a124. 
MASP-1 can also cleave C2 enhancing convertase formation and has been shown to 
activate MASP-2123. 
The classical pathway is initiated by the binding of the C1 complex, consisting of 
C1q and the serine proteases C1r and C1s, to the Fc portion of IgM and IgG 
antigen:antibody complexes clustering on the pathogen surface127. Binding of C1q causes 
a conformational change, activating C1r and leading to cleavage of C1s. Activated C1s 
will cleave C4 and C2 complement components, leading to the development of the C3 
convertase C4bC2a, similar to the lectin pathway.  
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The C3 convertase (C4bC2a or C3bBb) cleaves C3 and leads to binding of C3b 
onto the target surface and the release of the anaphylatoxin C3a, which recruits 
phagocytic cells to the site128. C3 is rapidly cleaved by the C3 convertase, leading to the 
development of more C3 convertases and the C5 convertase (C4bC2aC3b or 
C3bBb3b)129.  The C5 convertase cleaves C5 into C5a and C5b and can lead to the 
development of the major attack complex (MAC)124. The MAC, comprised of C5b, C6, 
C&, C8, and several C9 complement components, forms a transmembrane pore and 
disrupts the bilipid membrane leading to cell lysis128. 
Of the five major isotypes of immunoglobulin (IgA, IgD, IgE, IgG, IgM) that 
exist in the human immune system, IgG is by far the most prevalent and is one of the 
most abundant proteins found in human serum, accounting for approximately 10-20 % of 
total plasma protein130. Different classes of antibodies are generated following B cell 
activation in a process called class switch recombination, through which the constant 
heavy (CH) gene is excised causing a switch from Cµ to a different CH gene resulting in 
an isotypic switch from IgM131,132.  
Human IgG is very similar to the other isotypes of antibody in terms of its overall 
structure, consisting of two identical γ heavy (H) chains and two identical κ or λ light (L) 
chains, linked by disulfide bonds. The H chains are comprised of a variable domain (VH) 
and three constant domains (CH1, CH2, CH3), with a hinge region between CH1 and 
CH2133. The light chain is also comprised of variable chain (VL) and constant domain 
(CL). The fragment antigen binding or “Fab” portion of the antibody consists of the light 
chain associating with the VH and CH1 domains133. IgG responses to different antigen 
types lead to the skewing towards different subclasses of which there are four: IgG1, 
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IgG2, IgG3 and IgG4. Each of these subclasses has its own unique properties and 
functions within the immune system, and though they share 90% sequence identity in 
their constant domains, there is great variation in their hinge regions, leading to 
differences in their stability, flexibility, complement binding, and antigen binding 
capability130.  
IgG1 is the most abundant subclass of IgG in humans, accounting for 
approximately 60% of all serum IgG130. Predominantly induced in response to soluble 
and membrane-bound proteins/antigens, IgG1 is a strong activator of complement via the 
classical pathway134,135.  IgG2 antibodies are the second most abundant subclass and are 
primarily initiated by T-independent carbohydrate antigens, in extrafollicular responses, 
and have been shown to be a major isotype necessary for anti-bacterial antibody 
responses136. IgG2 shows poor complement fixation135. IgG3 antibodies, like IgG1, are 
produced primarily following interaction with T-dependent protein antigens and are also 
capable of initiating the complement cascade, with the strongest C1q binding of any IgG 
subclass135. Unlike IgG1, IgG3 antibodies are very short-lived with the lowest half-life of 
all IgG subclasses, at approximately 7 days137.  IgG4 antibodies are induced primarily 
following chronic antigenic stimulation and are unable to activate complement135,138,139.   
Mature B cells can be divided into three subsets: follicular (B2), marginal zone, 
and B1 cells. Marginal zone B cells, found in the spleen, consist of both memory B 
(BMEM) cells and mature naïve B cells
140. Within the follicular B (B2) cell subpopulation, 
located in the lymphoid follicles, there are phenotypically-unique subsets, characterized 
by specific surface markers that include transitional, germinal center (GC), and BMEM 
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cells, which are responsible for the bulk of adaptive humoral immune response. 
Additionally, there exists a minor subset of more innate-like B cells, termed B1 B cells.  
B1 cells are found primarily in the spleen, bone marrow, and peritoneal and 
pleural cavity with very little presence in circulation or lymph nodes and account for the 
production of approximately 80-90% of serum IgM141. Within the B1 cell subset, there 
are two distinct populations of cells. B1a (CD5+) cells, which are more innate-like and 
spontaneously produce “natural antibody”, typically low-affinity and polyreactive, which 
could be crucial in maintaining protection against pathogens in the time prior to germinal 
center formation, and B1b (CD5-) cells which function as a part of the adaptive immune 
response142–144.  B1b cells have been shown to induce long-lived T cell-independent IgM 
BMEM cells, which provide rapid protection against natural infections
145,146.  
B cells that interact with their cognate antigen and become activated in secondary 
lymphoid organs and receive T cell co-stimulation in the T zone, differentiate into 
plasmablasts in the medullary cords of the lymph node or extrafollicular foci of the 
spleen, or migrate to follicles, differentiating into germinal center B cells that proliferate 
and begin to form GCs, where long-lived plasma cells (LLPCs) and BMEM cells are 
formed. Plasmablasts proliferating in the extrafollicular space, have an average lifespan 
of 2-3 days and rapidly differentiate into short-lived plasma cells147. Short-lived plasma 
cells (SLPCs) initiated in the extrafollicular space have been shown to rapidly produce 
antibody and can persist for 3-4 weeks following initial infection/antigen 
interaction148,149.  
Extrafollicular B cell activation and humoral responses can be initiated in both T-
dependent (TD) and T-independent (TI) manners. TD extrafollicular responses can 
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induce class-switched antibody in a Bcl6-dependent manner150. While T follicular helper 
(TFH) cells are required for most class-switched antibody production, TI antigens, such as 
bacterial capsular polysaccharides, can initiate extrafollicular B cell humoral responses 
by activating marginal zone B cells to differentiate into plasmablasts and SLPCs.  These 
TI antibody responses do not often induce GC formation or BMEM/LLPC differentiation, 
and are associated with production of rapidly appearing and low-affinity antibodies149.  
Germinal centers are distinct structures which form within secondary lymphoid 
organs within 5-7 days after introduction of a foreign, TD antigen, either via 
immunization or infection151. Consisting of a both a light zone (LZ) and dark zone (DZ), 
germinal centers are critical for the development of long-lived humoral immunity and 
memory B cell populations. Within the light zone, signals are provided that sustain the 
GC B cell response. These signals are derived from B cell interactions with cognate 
antigen presented by follicular dendritic cells (FDCs) and co-stimulation provided by TFH 
cells. The GC is also where positive selection occurs for high-affinity clones152. In the 
dark zone of the GC, antigen-specific B cells undergo somatic hypermutation (SHM), 
during which the genes encoding the B cell receptor (BCR) are altered to allow for 
increased affinity for cognate antigen (i.e., somatic hypermutation). These DZ B cells 
then travel back to the LZ, where preferential activation leads to the positive selection of 
high-affinity clones, through affinity maturation153. High-affinity GC B cells are 
preferentially selected and differentiate into either BMEM or antibody-secreting cells 
(ASCs). Two types of ASCs are initiated, both SLPCs and LLPCs. Long-lived plasma 
cells migrate to the bone marrow and continue to produce high-affinity antibodies, while 
22 
 
SLPCs maintain residence in the draining lymph node or spleen and produce large 
amounts of antigen-specific antibodies154.  
Class switch recombination (CSR) and somatic hypermutation (SH), in the LZ of 
the GC, require the presence of activation-induced cytidine deaminase (AID)132,155. AID 
is upregulated in activated B cells, following CD40/CD40L interaction and in the 
presence of IL-4, and acts by deaminating cytosine in the target DNA and converting it to 
uracil. During somatic hypermutation, this deamination event induces a mismatch which 
results in DNA diversification either through the introduction of transition mutations or 
the removal of uracil by uracil DNA glycosylase (UNG) prior to replication, leading to 
point mutations in the variable region156–158.  In CSR, the deamination occurs upstream of 
the CH region of the immunoglobulin in the switch region. Uracil base pairs, introduced 
into both the donor and acceptor switch regions, are then excised by UNG causing 
double-strand breaks, which are then recombined to promote different CH through end-
joining recombination, resulting in the production of different classes of antibody158,159.  
Following immunization with TD antigens, antigen-specific B cells become 
activated and interact with TFH cells in the T zone through a process called linked 
recognition, in which the CD40/CD40L interaction provides necessary co-stimulation for 
B cell differentiation and maturation160. TFH cells are located within the lymph node 
follicle and upon interaction with foreign antigen, begin to downregulate CXCR9 on their 
cell surface, and upregulate CXCR5 expression, as well as CD40L and inducible T-cell 
costimulator (ICOS)161,162. TFH cell differentiation is largely regulated by B-cell 
lymphoma 6 (Bcl6), a transcription factor, that is necessary for the induction of TFH 
memory cell proliferation following rechallenge163–165.   
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This alteration in chemokine receptor expression (CXCR9 → CXCR5) stimulates 
the migration of T cells to the B cell follicle and GC LZ, to allow for interaction between 
B and TFH cells
166. The CD40/CD40L interaction induces CSR. TFH cells secrete IL-21, 
which is a key regulatory molecule that enhances immunoglobulin production and GC 
formation167. Lack of IL-21 during early stages of the humoral immune response, has 
been associated with increased levels of IgE and impaired IgG responses; however, there 
is no impact on the extrafollicular antibody response168,169. Additionally, loss of IL-21 has 
been shown to lead to shorten TFH and GC B cell lifespans, and presence of IL-21 has 
been linked to increased Bcl6 expression indicating that IL-21 plays a crucial role in the 
development of long-lived humoral immunity170–173.  
Located within the B cell follicle, FDCs are a major source of B cell activating 
factor (BAFF), IL-6, and IL-10 which are all critical for the differentiation of B cells 
within the germinal center174.  Presence of BAFF during early germinal center formation 
has also been associated with higher overall B cell proliferation and improved B cell 
survival175.  FDCs serve as the primary reservoir of antigen inside the B cell follicle, 
where they internalize and recycle complement-coated immune complexes and 
periodically display antigen on the cell surface to stimulate surrounding antigen-specific 
B cells176.   
Rapid development of a new population of SLPCs, following booster 
immunization or encounter with the target pathogen, is initiated by antigen-specific BMEM 
cells and IL-9, which is preferentially expressed on BMEM cells and upregulated following 
activation. IL-9 acts in an autocrine manner to upregulate proliferation and terminal 
differentiation of BMEM cells into antibody-secreting cells
178,179. BMEM cells, following 
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interaction with their cognate antigen, are responsible for initiating rapid germinal center 
formation, repopulating the existing BMEM pool, and differentiation into antigen-specific 
ASCs in as little at 3-5 days after initiation of the recall response180. BMEM cells, both 
class-switched and IgM+, have been shown to persist in the spleen of mice for over 400 
days post-immunization, and this response is independent of BAFF or a proliferation 
inducing ligand (APRIL)181,182. Characterized by their surface expression of CD38, 
CD19, and B220, antigen-specific BMEM cells are critical for initiating rapid recall 
antibody responses following interaction with their cognate antigen.  
Long-lived plasma cell maintenance in the bone marrow is not dependent on the 
presence of BMEM cells, antigen-loaded antigen-presenting dendritic cells, or secondary 
lymphoid structures183. It has been suggested that bone marrow CTLA4+ T regulatory 
(Treg) cells may play an important role in LLPC maintenance, with LLPC number 
decreasing by 50% when Treg cells are absent184.  
It has been shown that survival of long-lived ASCs in the bone marrow is 
dependent on presence of either BAFF and APRIL182.  BAFF and APRIL are both 
members of the tumor-necrosis factor (TNF) family, TNFSF13B and TNFSF13, 
respectively. BAFF is primarily produced by monocytes, DCs and macrophages and 
production is upregulated in the presence of IFN-γ and IL-10185–189. A TNF family 
receptor member, B cell maturation antigen (BCMA) provides necessary survival signals 
by binding to its ligands BAFF and APRIL190.  Studies on auto-immunity indicate that 
long-lived plasma cells numbers peak after about 12 weeks after activation, in the bone 
marrow191. As ASCs differentiate into long-lived plasma cells they downregulate FasR, 
CD19 and CD20, and upregulate CD138 and IL6R on their cell surface192.  LLPCs have 
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been shown to be metabolically unique from SLPCs in their ability to import higher rates 
of glucose for use in glycolysis and antibody glycosylation193. LLPCs express a wide 
variety of immunoglobulin production, though primarily produce IgA and IgG, and are 
most predominately found in the femur and lamina propria183,194.   
Long-term protection against pathogens, either conferred by vaccination or 
following natural infection, is largely facilitated through the continued presence of 
circulating high-affinity antibodies produced by LLPCs and through the rapid induction 
of new ASCs following infection (i.e., secondary immune response). When considering 
development of an efficacious vaccine that is able to induce both short and long-lived 
protective humoral immune responses, it is important to consider the activation of not 
only short-lived ASCs, but also BMEM cell populations, that are able to quickly respond to 
reinfection, and LLPCs that are able to produce antigen-specific antibodies over extended 
periods of time. It may be possible to identify promising new vaccine adjuvants by 
evaluating upregulation of IL-10 and IFN-γ and in the draining lymph node following 
immunization, as a way of predicting induction of BAFF/APRIL expression associated 
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Abstract 
Streptococcus pneumoniae is a major causative agent of pneumonia, a debilitating 
disease particularly in young and elderly populations, and is the leading worldwide cause 
of death in children under the age of five. While there are existing vaccines against S. 
pneumoniae, none are universally protective across all serotypes. Pneumococcal surface 
protein A (PspA), a key virulence factor of S. pneumoniae, is an antigen that may be 
incorporated into future vaccines to address the immunological challenges presented by 
the diversity of capsular antigens. PspA has been shown to be immunogenic and capable 
of initiating a humoral immune response that is reactive across approximately 94% of 
pneumococcal strains. Biodegradable polyanhydrides have been studied as a 
nanoparticle-based vaccine (i.e., nanovaccine) platform to stabilize labile proteins, to 
provide adjuvanticity, and enhance patient compliance by providing protective immunity 
in a single dose. In this study, we designed a room temperature stable PspA-based 
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polyanhydride nanovaccine that eliminated the need for a soluble protein component (i.e., 
100% encapsulated within the nanoparticles). Mice were immunized once with the lead 
nanovaccine and upon challenge, presented significantly higher survival rates than 
animals immunized with soluble protein alone, even with a 25-fold reduction in protein 
dose. This lead formulation performed similarly to protein adjuvanted with Alum, 
however, with much less tissue reactogenicity at the site of immunization. By eliminating 
the free PspA from the nanovaccine formulation, the lead nanovaccine was efficacious 
after being stored dry for 60 days at room temperature, breaking the need for maintaining 
the cold chain. Altogether, this study demonstrated that a PspA-based single dose 
nanovaccine against S. pneumoniae induced protective immunity and provided thermal 
stability when stored at room temperature for at least 60 days. 
 
Introduction 
Community-acquired pneumonia is a debilitating disease and is globally 
responsible for 16% of deaths in children under the age of five annually 1. Streptococcus 
pneumoniae, a causative agent of bacterial pneumonia, is a Gram-positive bacterial 
pathogen of humans, which colonizes the upper respiratory tract and leads to the 
development of potentially life-threatening diseases, such as otitis media, sinusitis, and 
pneumonia, with pneumonia being the most serious of these conditions 2,3. While otitis 
media and sinusitis are not as severe, they still account for seven million cases in the 
United States annually 3. S. pneumoniae is asymptomatically carried in approximately 
25% of healthy individuals and is spread between individuals through respiratory 
droplets, with children serving as the primary transmission source to adults (Althouse et 
al., 2017; Mendy et al., 2017; Quintero et al., 2011; Wyllie et al., 2017). Pneumococcal 
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infections are most prevalent in infants, young children, and the elderly, accounting for 
over $3 billion spent annually in direct healthcare spending; in addition, 60 to 87% of all 
pneumococcal bacteremia cases are associated with pneumonia in adults 3. While control 
of S. pneumoniae by antibiotics has been beneficial, up to 50% of all strains are resistant 
to erythromycin, with 97% of those also being resistant to azithromycin, making 
intervention strategies such as vaccination a necessary component of health care 
management 8. To date, the single most effective advance in the field of pneumonia 
prevention has been through immunization, though existing vaccines are still not 
completely effective 9,10.  
Current preventive strategies involve the use of pneumococcal polysaccharide 
vaccines (PPVs) and pneumococcal conjugate vaccines (PCVs). PPVs (T-independent 
antigens) are comprised of capsular polysaccharides, which are poorly immunogenic in 
very young and elderly individuals, while PCVs (T-dependent antigens) are more 
effective in these at-risk populations because of the adjoined protein component. While 
introduction of PPV23, PCV7, and PCV13 have had significant contributions in reducing 
the overall global burden of pneumococcal pneumonia, there is still room for 
improvement 11. As it currently stands, infection with strains not covered by vaccine 
serotype infections account for approximately 50% of all deaths in individuals over 55 
years of age 12. Additionally, it has been observed that introduction of new vaccine 
strategies against S. pneumoniae, such as the introduction of PCV10 immunization 
program for children in the Netherlands or use of PCV7 in Spain, may be directly 
correlated to an increased emergence of disease caused by non-vaccine serotype strains 
cases 13–15. It was demonstrated that PCV7 immunization, which contains the 19F 
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serotype antigen, actually caused an increase in pneumococcal infections by the the 
closely-related 19A serotype 16. Globally, this is of particular concern when considering 
the development of a universal vaccine, as it is now clear that the prevalence of certain 
serotypes differs greatly between age, geographic region, and ethnicity (Jedrzejas, 2001; 
Kristian et al., 2016; Rolo et al. 2009). PPV23 encompasses the most pneumococcal 
serotypes of the commercially available vaccines. However, it is not recommended for 
use in children under the age of 18 months because of their poor antibody response to T-
independent polysaccharide antigens, explaining why PCV13 is recommended for this 
age group. While the use of PCV and PPV vaccine formulations have effectively reduced 
the incidence of pneumococcal pneumonia, there is a need for newer vaccines to protect 
against the emergence of non-vaccine strains of S. pneumoniae 19. Coupled with the 
phase variation in expression of capsular and surface protein antigens, broadly protective 
vaccines against colonization and invasive pneumococcal disease are likely to require the 
inclusion of more conserved antigens that will also facilitate the induction of antigen-
specific CD4+ T cells 20,21. 
S. pneumoniae has several key virulence factors that play a critical role in 
colonization, transmission, and tissue damage including pneumolysin, two 
neuraminidases, and pneumococcal surface protein A (PspA). PspA is a choline binding 
protein, one of the most abundant proteins located on the pneumococcal cell surface, and 
has been shown to be of particular importance in facilitating nasopharyngeal colonization 
through inhibiting host complement responses 22. When considering the development of 
new vaccines against S. pneumoniae, it is important to consider a target immunogen that 
will be capable of inducing a broad, serotype-independent, protective immune response. 
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PspA has been of recent interest as a potential vaccine candidate due to its location on the 
cell surface of all 95 strains of S. pneumoniae currently known and its critical role in 
pneumococcal pathogenesis 2,23,24. Anti-PspA antibodies to clades 1 and 2 of PspA have 
been shown to be cross-protective against S. pneumoniae strains encompassing all six 
clades of PspA, and provide protection when passively transferred to naïve mice as a 
therapeutic intervention following septic S. pneumoniae challenge 17,25–27. The ability to 
provide protection across many serotypes of S. pneumoniae using only two clades of 
PspA allows for the design of a broadly cross-protective vaccine when compared to 
vaccines containing numerous capsular polysaccharides.  
Polyanhydride nanoparticle-based vaccines (i.e., nanovaccines) represent next 
generation vaccine platforms against pathogens such as S. pneumoniae. These 
nanovaccines are formulated using random copolymers based on 1,8-bis-(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-bis-(p-carboxyphenoxy)hexane (CPH), 
and sebacic acid (SA) and have been extensively studied as a nanovaccine platform 
against infectious pathogens such as influenza virus, Yersinia pestis, and Bacillus 
anthracis 28–31.  
Polyanhydrides provide vaccine delivery benefits and adjuvant properties that make them 
well suited as a vaccine delivery platform. These materials exhibit high biocompatibility 
with minimal injection site reactivity 32–34 (i.e., tenderness, swelling, and pain) in 
comparision to traditional adjuvants, such as Alum, which has been associated with 
immunization site tenderness and pain, and are currently FDA-approved for use to treat 
malignant gliomas in the brain 35,36. In addition, polyanhydrides are hydrophobic and 
exhibit surface erosion characteristics, which helps stabilize labile proteins, protects 
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protein denaturation from enzymatic cleavage and acidic degradation products, and 
allows for the prolonged release of antigen 28,37–41. The sustained release of antigen 
allows for enhanced bioavailability of antigen to drive adaptive immune responses and 
allows for single dose administration and dose-sparing capabilities 29,42–44. Previous work 
has shown that mice immunized with a single dose of nanovaccine encapsulating Y. pestis 
fusion protein F1-V were completely protected against Y. pestis lethal challenge after at 
least 280 days post-immunization (DPI) 31. Varying polyanhydride copolymer 
composition has shown to modulate internalization and persistence within APCs in vitro, 
as well as induction of both cellular and humoral immune responses in vivo indicating the 
ability to tailor polymer chemistry in order to rationally design nanovaccines that 
optimally inducing antigen-specific protective immunity 31,42,45–54. 
Previous work from our laboratories has demonstrated that PspA encapsulated 
into nanoparticles maintained its stability, conformational structure, as well as biological 
activity upon release, which was measured using an apolactoferrin binding assay 38. In 
this same work, mice immunized with a single dose of the nanovaccine generated robust 
antibody titer and avidity to PspA, equivalent to that of antigen adjuvanted with MPLA. 
However, the protective efficacy of a PspA-based nanovaccine against lethal challenge 
has not been demonstrated. In this study, the ability of various polyanhydride 
nanovaccine chemistries as vaccine candidates was evaluated and it was demonstrated 
that a lead PspA-based nanovaccine protected animals against lethal challenge with a 25-
fold reduction in overall PspA dose. Further, this lead formulation was shown to be 




Materials and Methods 
Materials 
Chemicals used for monomer and polymer synthesis included sodium hydroxide, 
hydrobenzoic acid, dibromohexane, 1-methyl-2-pyrrolidinone, sebacic acid monomer, 
and triethylene glycol purchased from Sigma Aldrich (St. Louis, MO). Acetic anhydride, 
ethyl ether, petroleum ether, chloroform, methylene chloride, hexane, acetone, sulfuric 
acid, potassium carbonate, dimethyl formamide, toluene, acetonitrile, N,N-
dimethylacetamide, and acetic acid were purchased from Fisher Scientific (Fairlawn, NJ); 
4-p-fluorobenzonitrile was purchased from Apollo Scientific (Cheshire, UK).  For 1H 
NMR analysis of the copolymers, deuterated chloroform and dimethyl sulfoxide were 
purchased from Cambridge Isotope Laboratories (Andover, MA). The N-terminal region 
of a recombinant PspA (UAB055, PspA/Rx1 AA1 to 303, clade 2 PspA of the PspA 
family 1) was produced by Dr. David McPherson (University of Alabama at 
Birmingham) as described previously 55. Prior to immunization, endotoxin was removed 
from the protein using endotoxin removal beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions followed by dialysis and 
lyophilization. The final endotoxin content of the protein was determined to be less than 
1.9 EU/mg as determined by a limulus amebocyte lysate (LAL) chromogenic endotoxin 
quantification kit (Thermo Fisher Scientific). 
Copolymer and Nanoparticle Synthesis 
Monomers of CPH and CPTEG were synthesized as previously described 28,47. A 
50:50 molar composition copolymer of CPH and CPTEG and a 20:80 molar composition 
copolymer of CPH and SA was synthesized using melt condensation as described by 
Torres et al. 28. PspA protein, 1% (w/w), was encapsulated into polyanhydride 
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nanoparticles using solid/oil/oil nanoprecipitation, as previously described 38. Excess 
buffer was removed from PspA protein solution using a 5 kDa MWCO dialysis 
microcentrifuge tube and the resulting protein solution was lyophilized overnight at -40 ̊C 
under vacuum. The lyophilized protein and the respective copolymer was then dissolved 
in methylene chloride at a concentration of 20 mg/mL of solvent. The solution was 
sonicated using the VibraCell ultrasonic probe (Sonics & Materials, Inc., Newton, CT) to 
ensure complete dissolution and homogenization of the protein and the copolymer. The 
resulting solution was then added to pentane at a 1 to 200 (v/v) ratio of methylene 
chloride to pentane at 20°C for the 20:80 CPH:SA nanoparticle formulation or at a 1 to 
250 (v/v) ratio of methylene chloride to pentane at -40°C and for the 50:50 CPTEG:CPH 
nanoparticle formulation. Nanoparticles were collected using vacuum filtration. Surface 
charge of representative 20:80 CPH:SA and 50:50 CPTEG:CPH nanoparticle 
formulations were measured using quasi-elastic light scattering (QELS, Zetasizer Nano, 
Malvern Instruments Ltd., Worcester, UK). 
Animals 
CBA/CaHN-Btkxid/J (CBA/N) mice were purchased from Jackson Laboratory 
(Bar Harbor, ME). These mice, which have a mutation in their Bruton’s tyrosine kinase 
gene, were used for the immunization studies. Due to this mutation, these mice are unable 
to initiate a proper antibody response to Type II thymic-independent antigens (e.g., 
capsular polysaccharides), and are thus able to better mimic natural antibody responses in 
at-risk elderly or young populations. Mice were housed under specific pathogen-free 
conditions where all bedding, caging, water, and feed were sterilized prior to use. All 
studies were conducted with the approval of the Iowa State University Institutional 




Groups of 8-10 CBA/N mice were immunized subcutaneously at the nape of the 
neck with 0 to 20 µg PspA, 0 to 5 µg PspA encapsulated into 50 to 500 µg polyanhydride 
nanoparticles, and/or 50 µL of Imject Alum Adjuvant (ThermoFisher Scientific) and 
delivered in a total volume of 100 µL. Immunization groups for the individual studies 
(see Tables 1 and 2) were comprised of: i) 25 µg soluble PspA alone, ii) 25 µg PspA 
administered with 50 µL Imject Alum, iii) 5 µg PspA encapsulated into 250 µg 50:50 
CPTEG:CPH nanoparticles + 20 µg soluble PspA, iv) 5 µg PspA encapsulated into 250 
µg 20:80 CPH:SA nanoparticles + 20 µg soluble PspA, v) 1 µg soluble  PspA alone, vi) 1 
µg PspA administered with 50 µL Imject Alum, vii) 1 µg PspA encapsulated into 50 µg 
50:50 CPTEG:CPH nanoparticles, viii) 0.5 µg PspA encapsulated into 25 µg 50:50 
CPTEG:CPH nanoparticles + 25 µg  blank 50:50 CPTEG:CPH nanoparticles + 0.5 µg 
soluble PspA, or ix) saline control. Blood was collected from mice via saphenous vein 
and serum was isolated following centrifugation (10,000 rcf for 10 min) at days 17 or 21 
DPI. Serum was stored at -20°C until analysis could be performed. 
S. pneumoniae Challenge 
S. pneumoniae strain A66.1, of PspA family 1, clade 2 was used for challenge and 
grown as previously described 56,57. Briefly, the bacteria was grown at 37°C for 18 hours 
in filter-sterilized Todd-Hewitt broth with 0.5% yeast extract, and stored at -80°C at a 
concentration of 1 x 108 CFU/mL. Inoculum was diluted to a concentration of 2.5 x 104 
CFU/mL in sterile PBS and 100 µL was administered intravenously at 24 DPI. Mice were 
monitored three times per day for the duration of the challenge (14 days). Body 
temperatures and body condition scores were also recorded once per day. Mice were 
sacrificed when determined to be moribund or at 14 days post-challenge. 
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Anti-PspA Antibody Titer  
Anti-PspA antibody titers were determined via an ELISA as described previously 
38. Briefly, high-binding Costar 590 EIA/RIA microtiter plates (Corning) were coated 
overnight at 4 °C with 0.5 µg/mL PspA. The blocking buffer for this assay was 
comprised of 2.5% (w/v) powdered milk dissolved in PBS-T and incubated for two hours 
at 56°C to inactivate any endogenous phosphatase activity. PspA-coated plates were 
incubated with blocking solution for two hours at room temperature before being washed 
three times with PBS-T. Serum obtained from immunized mice was added to the first 
well of a row at a dilution of 1:200 and serially diluted in PBS-T containing 1% (v/v) 
goat serum. Each serum sample was tested in duplicate. Following incubation overnight 
at 4°C, plates were washed three times with PBS-T after which secondary antibody was 
added at a dilution of 1 µg/mL. The secondary antibody used in these studies was 
alkaline phosphatase-conjugated goat anti-mouse IgG heavy and light chain (Jackson 
ImmunoResearch) and was incubated on the plates for two hours at room temperature. 
Plates were then washed three times with PBS-T and alkaline phosphatase substrate 
(Fisher Scientific, Pittsburgh, PA) was added at a concentration of 1 mg/mL dissolved in 
50 mM sodium carbonate, 2 mM magnesium chloride buffer at pH 9.3 for colorimetric 
development. Plates were analyzed after 30 min using a SpectraMax M3 microplate 
reader at a wavelength of 405 nm. Titer is reported as the reciprocal of serum dilution at 
which optical density value was at least twice that of the saline group average plus two 
standard deviations.  
Shelf Stability of Stored PspA Nanovaccine 
Shelf stability of the PspA nanovaccine was assessed via ELISA and lethal 
challenge. 50:50 CPTEG:CPH nanoparticles encapsulating PspA were taken out of the 
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freezer (-80 °C) and stored as a dry powder formulation at 25 °C (room temperature) in a 
glass desiccator containing drierite for 60 days prior to immunization. Soluble PspA was 
stored at 4°C and combined with Imject Alum prior to immunization. A separate group of 
nanoparticles were kept in the freezer over the course of this experiment as a freezer-
stored standard control. Following room temperature storage, vaccine efficacy was 
evaluated by immunizing mice with a nanovaccine dose equivalent to 1 μg PspA per 
animal from one of the storage conditions above, soluble PspA adsorbed to Alum, or the 
saline control and assessing antibody titer via ELISA 21 DPI (see ‘Anti-PspA Antibody 
Titer’ section for details). Following lethal challenge with 2500 CFU of S. pneumoniae 
(see S. pneumoniae challenge section for details), survival was assessed over the next 24 
days.   
Statistical Analyses 
Statistical analyses were performed using the Gerhan-Breslow-Wilcoxon test and 
the one-way analysis of variance (ANOVA) using Tukey’s multiple comparisons test. A 
p-value ≤ 0.05 was considered statistically significant. All analyses were performed using 
GraphPad Prism v. 7.0 software.  
Results 
Synthesis and characterization of PspA-encapsulated polyanhydride nanoparticles 
The nanoparticle chemistries chosen for the current study were based on 50:50 
CPTEG:CPH and 20:80 CPH:SA copolymers, consistent with our previous work, in 
which these chemistries were shown to provide protein structural stability and maintain 
the functional activity of PspA following release 38. The nanoparticles were synthesized 
using solid/oil/oil emulsion 48. The PspA release kinetics from these formulations are 
described in our previous work 38. Scanning electron photomicrographs of the 
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nanoparticles revealed similar sizes for the two formulations, with sizes of 455 ± 175 nm 
and 422 ± 163 nm for 50:50 CPTEG:CPH and 20:80 CPH:SA nanoparticles, respectively 
(Figure 2.1). Zeta potential measurements of empty 20:80 CPH:SA and 50:50 
CPTEG:CPH nanoparticles revealed that the particles had a negative surface charge, with 
zeta potentials of -41.9 ± 0.9 mV and -33.1 ± 5.1 mV, respectively, consistent with 
previous publications 49,53,58. 
 
Figure 2.1 PspA nanovaccine characterization. Representative scanning electron 
photomicrographs of (A) 2% PspA-loaded (w/w) 20:80 CPH:SA nanoparticles and (B) 
2% PspA-loaded (w/w) 50:50 CPTEG:CPH nanoparticles (scale bar = 5 μm). (C) Particle 
size distribution of 2% PspA-loaded (w/w) 20:80 CPH:SA nanoparticles (422 ± 163 nm). 
(D) Particle size distribution of 2% PspA-loaded (w/w) 50:50 CPTEG:CPH nanoparticles 
(455 ± 175 nm). 
 
Immunization with PspA-based nanovaccines induces protective antibody response 
Previously, it was demonstrated that mice vaccinated with PspA-based 
nanovaccines induced a robust humoral response, however protective efficacy was not 
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evaluated 38. In the current studies, separate groups of CBA/CaHN mice (n = 8 per group) were 
immunized subcutaneously as follows: i) 25 µg soluble PspA alone, ii) 25 µg PspA administered 
with Imject Alum, iii) PspA-containing 50:50 CPTEG:CPH nanoparticles , iv) PspA-containing 
20:80 CPH:SA nanoparticles, or v) saline (Table 2.1). Both the nanovaccine formulations 
contained 5 µg of encapsulated PspA along with 20 µg of soluble protein, as shown in Table 1. 
Anti-PspA total IgG titers were evaluated at 17 DPI and there were no significant differences in 
titer between vaccinated groups (Figure 2.2A). Mice were challenged with a lethal dose of S. 
pneumoniae strain A66.1 at 24 DPI and survival was assessed over a period of two weeks. All 
PspA naïve (saline) mice succumbed to infection within four days, while all the immunized 
animals showed prolonged survival following challenge. At 14 days post-challenge, only 25% of 
the (non-adjuvanted) soluble PspA-immunized animals survived, whereas adjuvanting the 
protein with alum provided 100% protection. Immunization with the 20:80 CPH:SA nanovaccine 
resulted in 87% survival, while 100% of the animals immunized with 50:50 CPTEG:CPH 
nanovaccine were protected, as shown in Figure 2.2B. The survival data, in correlation with the 
antibody titers indicate that not only is PspA an effective immunogen, but induces protective 
immunity when delivered with an adjuvant. Though both nanoparticle chemistries protected 
animals from lethal challenge compared to saline, the 50:50 CPTEG:CPH PspA nanovaccine 
performed significantly (p ≤ 0.008) better than sPspA alone. Based on these results, we selected 





Table 2.1 PspA Vaccine Formulations.  25 µg PspA containing single dose vaccine treatments groups. Separate groups of mice 
were immunized s.c. and all formulations were delivered in 100 µL total volume. Soluble PspA is represented as sPspA, and 
nanoparticle-encapsulated PspA is represented as ePspA. 
 
Formulation sPspA (µg) ePspA (µg) 
50:50 CPTEG:CPH PspA Nanovaccine 20 5 
20:80 CPH:SA PspA Nanovaccine  20 5 
sPspA + Alum 25 0 
sPspA 25 0 
Saline 0 0 
 
Figure 2.2  PspA nanovaccines are capable of initiating protective immune responses. (A) Serum was collected from 
immunized mice (see Table 1) at 17 DPI and analyzed for total anti-PspA IgG (data is represented as log10) using ELISA. 
Dashed line represents background anti-PspA IgG levels in serum from the saline-immunized mice. (B) S. pneumoniae 
challenge was performed at 24 DPI by i.v. administration of 2500 CFUs of A66.1 strain and survival was monitored for 14 
days post-challenge. * indicates significance (p ≤ 0.0025) compared to sPspA alone and # indicates significance (p ≤ 0.001) 
compared to saline treated mice. Data is representative of single experiment containing n = 8 mice per treatment group. 
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PspA nanovaccine demonstrates dose-sparing capabilities  
Rational design of vaccines using subunit proteins involves considering total cost 
of the end product, as well as protein availability that potentially impacts vaccine 
shortages. Our previous work has shown that encapsulating a lowered dose of antigen 
into polyanhydride nanoparticles can induce a robust immune response 44. In the current 
studies, the ability of the nanovaccine to provide dose-sparing (i.e., 25-fold reduction) 
was evaluated by immunizing separate groups of CBA/N mice (n = 8 per group; see 
Table 2.2) subcutaneously using the following regimens: i) 1 µg PspA encapsulated into 
50:50 CPTEG:CPH nanoparticles (PspA Nanovaccine), ii) 0.5 µg PspA encapsulated into 
50:50 CPTEG:CPH nanoparticles plus 0.5 µg soluble PspA (PspA Nanovaccine + 
Soluble PspA), iii) 1 µg soluble PspA administered with Imject Alum, iv) 1 µg soluble 
PspA alone, and v) saline alone (i.e., naïve control). Serum was collected at 21 DPI and 
analyzed for total anti-PspA IgG. Mice immunized with the nanovaccines or PspA + 
Alum showed significantly (p ≤ 0.008) higher titers to PspA compared to soluble PspA 
alone (Figure 2.3A). Survival rates following lethal challenge showed significantly (p ≤ 
0.001) higher survival (87.5%) in mice immunized with both the nanovaccine 
formulations compared to animals immunized with soluble PspA (12%) (Figure 2.3B). 
Animals immunized with PspA adjuvanted with Alum performed similarly to the animals 
receiving the nanovaccine formulations. There were no observable differences in disease 
severity between the immunized animals, as measured by body condition scores and 
temperature (data not shown). Additionally, soluble PspA administered in conjunction 
with 100 µg of empty 50:50 CPTEG:CPH nanoparticles, performed similarly to other 
adjuvanted groups, further indicating the ability for PspA to initiate a protective immune 
response when adjuvanted properly (data not shown).  No significant differences in 
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survival were observed between mice immunized with PspA fully encapsulated within 
the nanoparticles (i.e., PspA Nanovaccine) and animals that received half of the protein 
as a soluble bolus (i.e., PspA Nanovaccine + Soluble PspA). Eliminating the use of 
soluble PspA in the nanovaccine is beneficial when designing a shelf-stable dry powder 
formulation for the long-term storage of a PspA nanovaccine.  
Table 2.2 Dose-sparing PspA vaccine formulations. One µg PspA containing single dose 
vaccine treatments groups. Separate groups of mice were immunized s.c. and all 
formulations were delivered in 100 µL total volume. Soluble PspA is represented as 
sPspA, and nanoparticle-encapsulated PspA is represented as ePspA. 
Formulation sPspA (µg) ePspA (µg) 
PspA Nanovaccine 0 1 
PspA Nanovaccine + sPspA 0.5 0.5 
sPspA + Alum 1 0 
sPspA 1 0 




PspA nanovaccine maintains efficacy following room temperature storage 
To evaluate the potential for a room temperature stored (i.e., non-refrigerated) PspA 
nanovaccine, 1 µg of PspA was encapsulated within 50 µg of 50:50 CPTEG:CPH 
nanoparticles (i.e., 2 wt.% loading) and stored at room temperature (25°C) and standard 
storage conditions (-80°C), as detailed in the methods section and as previously described 













Figure 2.3 Nanovaccines with 25-fold reduction in total protein provided protection against lethal challenge.  (A) Serum was 
collected from immunized mice (see Table 3) at 21 DPI and analyzed for total anti-PspA IgG (data is represented as log10) 
using ELISA. Dashed line represents background anti-PspA IgG levels in the serum from the saline-immunized mice. * 
indicates significance (p ≤ 0.008) compared to sPspA alone. (B) S. pneumoniae challenge was performed at 24 DPI by i.v. 
administration of 2500 CFUs of A66.1 strain and survival was monitored for 14 days. * indicates significance (p ≤ 0.003) 
compared to sPspA alone and # indicates significance (p ≤ 0.0002) compared to saline treated mice. Data is representative of 
single experiment containing n = 8 mice per treatment group. 
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The soluble PspA was stored at 4°C and mixed with Alum prior to immunization. 
Following storage, separate groups of mice (n= 8-10 per group) were immunized 
subcutaneously with the PspA nanovaccine stored at the different conditions or with 
alum-adjuvanted PspA and serum was collected and analyzed at 21 DPI. Storage 
conditions did not have a significant effect on anti-PspA IgG titers, with all of the PspA 
nanovaccines performing similarly (Figure 2.4A). Mice were then challenged with a 
lethal dose of S. pneumoniae at 24 DPI and survival was monitored for two weeks. All of 
the non-immunized mice succumbed to challenge within four days post challenge, while 
the nanovaccine-immunized mice presented with 60-70% survival with a single dose 
(Figure 2.4B). Once again, no significant differences were observed between the survival 
rates of mice immunized with the PspA nanovaccine stored at various conditions and 
those immunized with soluble PspA adjuvanted with Alum. This data indicates that the 
PspA nanovaccine is efficacious when stored both in the freezer or at room temperature 
for time periods up to 60 days and performs similarly to refrigerated PspA adjuvanted 
with Alum.  
Discussion 
Streptococcus pneumoniae is a causative agent of debilitating bacterial 
pneumonia. While many existing vaccines have proven to be valuable in reducing overall 
global disease burden, none are without limitations. Newly developed vaccine strategies 
against S. pneumoniae have identified several novel antigens, including PspA. Anti-PspA 
antibodies have been observed, following natural colonization or infection in children 
59,60. Other studies have shown success, against lethal intranasal or septic S. pneumoniae 
challenge by vaccinating with PspA which further indicates its potential as an efficacious 








Figure 2.4 Room temperature-stored PspA nanovaccine maintains efficacy after 60 days.  (A) Serum was collected from 
groups of immunized mice at 21 DPI with vaccine stored at different conditions as indicated and analyzed for total anti-PspA 
IgG (data is represented as log10) using ELISA. Dashed line represents background anti-PspA IgG levels in the serum from the 
saline-immunized mice. (B) S. pneumoniae challenge was performed at 24 DPI by i.v. administration of 2500 CFUs of A66.1 
strain and survival was monitored for 14 days. * indicates significance (p ≤ 0.001) compared to saline treated mice. Data is 




Aluminum hydroxide (i.e., Alum)-based adjuvants are widely used because of 
their ability to promote Th2 immune responses 62. However, Alum-based vaccines are 
associated with higher levels of immunization site tissue reactogenicity (Chen and 
Kristensen, 2009; Levy et al. 2013). Immunization-site tenderness and pain are the most 
commonly reported symptoms following immunization with vaccines containing Alum. 
Prevalence of these adverse reactions has been found to be directly associated with 
increased protein dose administered and decreased age of the vaccinated individuals 
(Brady et al., 2009; Petrovsky 2015; Willhite et al. 2014). Previous work with 
polyanhydride nanovaccines have shown low-level tissue site inflammation and toxicity 
making them a safe alternative to traditional vaccine adjuvants 34,41,68. Therefore, 
nanovaccines may represent a safe and efficacious alternative to Alum-based vaccines, 
which have limitations associated with administration site reactogenicity and only 
promote humoral immune responses against PspA.  
Work from other laboratories has shown limited success using nanotechnology 
vaccine platforms with PspA in various animal models though, to date, none of these 
studies have shown protection against lethal challenge with single-dose immunization 69–
71. Previous work from our laboratories has indicated that encapsulation of PspA into 
polyanhydride nanoparticles is capable of retaining protein structure and function, which 
enabled initiation of a humoral immune response 38. Building upon these studies, PspA 
was encapsulated within both 50:50 CPTEG:CPH and 20:80 CPH:SA nanoparticle 
formulations in the current work. Both formulations produced nanoparticles of similar 
size and size distribution (Figure 2.1). The size, morphology and size distribution of these 
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particles were similar to those previously reported for these formulations28,29,38,42. 
Following subcutaneous immunization of mice with a single dose of either formulation, 
anti-PspA IgG antibodies were produced, in agreement with our previous findings 38. 
Following lethal septic challenge, both nanovaccine formulations (containing 25 µg 
PspA) were capable of conferring protective immunity in mice, with 87.5% survival in 
20:80 CPH:SA nanovaccine immunized mice and 100% protection in those that received 
the 50:50 CPTEG:CPH nanovaccine (Figure 2.2). Based on the increased protection and 
higher antibody titers observed following immunization with a single dose of the 50:50 
CPTEG:CPH nanovaccine formulation, this chemistry was selected as the lead candidate 
nanovaccine.   
Reducing the amount of protein necessary per dose can greatly reduce the cost 
associated with using a recombinant protein vaccine, thereby allowing for the production 
and storage of more doses. Most of the published reports evaluating PspA-based vaccine 
success immunized mice with a minimum of 5 µg of antigen plus an adjuvant and 
required multiple boosts 56,61,72,73. Indeed, a recent report demonstrated complete 
protection in mice receiving 0.5 µg of PspA adjuvanted with poly(I:C) intranasally; 
however, the immunization schedule required three doses to provide protection 73. The 
need for a single dose vaccination regimen cannot be overstated from a patient 
compliance standpoint because according to the WHO, an estimated 29% of children 
aged one month to five years die each year from vaccine preventable diseases, citing non-
compliance with the immunization regimen as a key reason for lack of successful 
national vaccination programs 74. Therefore, single-dose vaccines can aid in improving 
patient compliance, reduce cost, and improve national immunization rates worldwide. 
61 
 
Recent work from our laboratories has demonstrated that 25 µg of ovalbumin 
encapsulated into polyanhydride microparticles was able to elicit robust antibody titers 
equivalent to a 16x larger soluble dose of ovalbumin while 25 µg of soluble ovalbumin 
alone was unable to elicit detectable antibody responses 44. In order to corroborate these 
results with PspA, the dose of antigen evaluated was reduced 25-fold to 1 µg. 
Immunization with the 1 µg PspA-based 50:50 CPTEG:CPH nanovaccine formulation, 
both with and without soluble PspA, induced production of high anti-PspA IgG titers 
(Figure 2.3A), with very little reduction in overall antibody titer compared to the previous 
study with a 25 µg dose of PspA (i.e., data in Figure 2.2). Antibody titers were similar 
between mice immunized with 1 µg of soluble PspA administered with Alum or with the 
nanovaccine formulations, with the highest overall titers observed in mice immunized 
with the fully-encapsulated nanovaccine formulation. When compared to soluble protein 
adjuvanted with Alum, mice immunized with the 50:50 CPTEG:CPH nanovaccine were 
similarly protected from lethal challenge. Furthermore, 87.5% of the animals challenged 
with the reduced dose PspA nanovaccine (with or without soluble PspA) were protected 
(Figure 2.3B). These data demonstrate that reducing the protein dose by 25-fold had little 
effect on survival, with both the fully encapsulated PspA nanovaccine and the 
nanovaccine administered with a soluble bolus providing significantly higher survival 
following lethal challenge, compared to soluble protein alone.  
By eliminating the soluble protein component from vaccine formulations, 
nanovaccines can be stored as a dry powder outside of refrigeration with the potential for 
long-term shelf storage, thereby circumventing the cold chain. As it currently stands, all 
prequalified WHO vaccines require refrigeration 74. Nanovaccines may enable next-
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generation vaccines to be stored without the need for refrigeration (i.e., eliminating the 
cold chain), allowing for vaccines to be sent to remote locations in need for vaccination, 
resulting in reduced medical costs and productivity losses associated with disease 75. 
Previous work from our laboratories demonstrated that nanovaccines encapsulating PspA 
were able to retain protein structure and activity following release, and a nanovaccine 
encapsulating the Bacillus anthracis protective antigen (PA) released biologically and 
immunologically functional protein following storage at both room temperature and 
above after four months 28,38. In contrast, aluminum salt-based adjuvants have been 
reported to alter the structure of proteins and decrease thermal stability following 
adsorption 76, and previous work from our laboratories has shown that PA adsorbed to 
alum lost its functional activity when stored for four months at refrigerated conditions or 
above 28. Following storage at room temperature for 60 days, the PspA nanovaccine was 
shown to be efficacious, as measured by antibody titer and survival (Figure 2.4). PspA 
adsorbed to alum performed similarly, however, because PspA is a stable protein with 
coiled structure, it is likely that differences may be observed between the efficacy of the 
nanovaccine and alum-based formulations following storage for an extended period of 
time, or at elevated temperature, and should be evaluated in future studies 22. As such, 
this work indicates that the PspA nanovaccine formulation can be stored as a dry powder 
for at least 60 days while maintaining its immunogenicity.  
In summary, this work describes the design of a safe next-generation PspA-based 
pneumonia nanovaccine with dose-sparing, protective immunity, and enhanced room 
temperature storage. These studies are promising first steps with respect to establishing 
the polyanhydride nanovaccine platform as an alternative to traditional vaccines in terms 
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of reduced cost (enabled by the dose sparing and single dose capabilities) and difficulties 
associated with transportation and storage of vaccines in developing countries (enabled 
by the superior room temperature storage capabilities). 
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Yersinia Pestis, the causative agent of pneumonic plague, induces a highly lethal 
infection if left untreated. Currently, there is no FDA-approved vaccine against this 
pathogen; however, USAMRIID has developed a recombinant fusion protein, F1-V, that 
has been shown to protect multiple animal species against pneumonic plague. Many F1-
V-based vaccine formulations require prime-boost immunization to achieve protective 
immunity, and there are no reports of rapid induction of protective immunity (i.e., 14 
days post-immunization (DPI)). The STimulator of INterferon Genes agonists cyclic 
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dinucleotides (CDNs) have been shown to be promising vaccine adjuvants. 
Polyanhydride nanoparticle-based vaccines (i.e., nanovaccines) have also been shown to 
enhance immune responses due to their dual functionality as both an adjuvant and a 
delivery platform. Utilizing the synergy provided by these two platforms, a combination 
nanovaccine was designed that comprised F1-V-loaded nanoparticles combined with the 
CDN, dithio-RP,RP-cyclic di-guanosine monophosphate (R,R-CDG), to induce rapid and 
long-lived protective immunity against pneumonic plague. All mice immunized with a 
single dose combination nanovaccine were protected from Y. pestis lethal challenge 
within 14 DPI, and demonstrated significantly enhanced protection over a soluble bolus 
of F1-V adjuvanted with CDNs. In addition, 75 percent of mice were protected from 
challenge at 182 DPI, while maintaining high levels of antigen-specific serum IgG. 
ELISPOT analysis of vaccinated animals at 218 DPI revealed the presence of F1-V-
specific long-lived plasma cells in the bone marrow. Microarray analysis of linearly 
overlapping peptides revealed the presence of serum antibody with high affinity for a 
broad range of F1 and V linear epitopes. Altogether, these results demonstrate that 
combining the adjuvanticity of CDNs with a nanoparticle-based vaccine delivery system 
enables induction of both rapid and long-lived protective immunity against Y. pestis. 
 
Introduction 
Plague has relentlessly affected humans throughout history accounting for an 
estimated 200 million deaths 1,2 and continues to persist worldwide, with the latest 
outbreak occurring in Madagascar in 2017. Plague is caused by the non-motile, 
facultative intracellular, Gram-negative bacterium Yersinia Pestis 3. Pneumonic plague, 
the respiratory manifestation of Y. pestis infection, is transmitted through aerosolized 
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droplets 4. In the case of pneumonic plague, treatment with intravenous or oral 
ciprofloxacin and doxycycline over 48 hours is successful, though mortality rates quickly 
approach 90-100% if left untreated for 24-36 hours post-infection 1.  
The threat of weaponization of Y. pestis is high, largely evidenced by its history of 
such use 2. Though the United States and 103 other countries co-signed an agreement to 
terminate biological weapons programs in 1972, Y. pestis remains listed as a Tier 1 Select 
Agent. Currently, there is no FDA-approved vaccine against Y. pestis, making it critical 
to develop a protective vaccine with the capability to provide both rapid and long-lived 
immunity in the event of mass exposure of aerosolized Y. pestis to civilian or military 
populations. As Y. pestis is predominantly an extracellular pathogen, many vaccination 
strategies have focused on developing strong humoral immunity, characterized by 
neutralizing antibodies against the V antigen and opsonizing antibodies against the F1 
capsule 5–8. In mice, anti-F1 IgG antibody titers have been shown to correlate with 
protection 5. Additionally, mAb 7.3, which binds to the V antigen, has been shown to 
neutralize Y. pestis in vitro and provides passive protection against lethal challenge 6,9. 
The United States Army Medical Research Institute of Infectious Diseases 
(USAMRIID) developed a recombinant fusion protein F1-V, containing both full length 
proteins of both F1 and V, and shows promise as a target antigen for Y. pestis 10. Using a 
IM/SC prime-boost regimen, it was recently shown that F1-V adjuvanted with aluminum 
hydroxide (alum) provided complete protection against intranasal challenge with virulent 
Y. pestis CO92 in mice, guinea pigs, and macaques 11. Additionally, serum collected from 
immunized macaques conferred passive protection to mice. Despite such success, this 
vaccine formulation requires a prime-boost regimen; in the event of mass exposure, it 
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would be ideal to use single dose formulations that can provide rapid immunity in as 
short a time frame as possible and that can maintain long-lived protective immunity. 
Cyclic dinucleotides (CDNs), a class of small molecule adjuvants, are recognized 
as microbial-associated molecular patterns (MAMPs) by the pattern recognition receptor 
(PRR) STING (STimulator of INterferon Genes) 12, resulting in the phosphorylation of 
transcription factors NFκB and IRF3 and the induction of type I interferons (IFNα and 
IFNβ) which are associated with anti-pathogenic activity 13,14. Cyclic di-GMP (CDG), the 
most well-studied CDN to date, has been recognized as a universal secondary messenger 
molecule in Gram-negative bacteria, playing a role in bacterial development, motility, 
and virulence 15. Vaccines adjuvanted with CDG induce a balanced immune response, 
characterized by equal presence of IgG subclasses in serum 16, and have been shown to 
elicit significantly higher antibody titers than alum-adjuvanted formulations 17.  
Biodegradable polyanhydrides, another novel class of adjuvants and delivery 
vehicles, possess a multitude of beneficial characteristics to address challenges faced by 
many current vaccines 18. Comprised of 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), these materials are highly 
biocompatible, demonstrating minimal injection-site reactivity when administered as 
particles 19,20 and whose non-toxic dicarboxylic acid degradation products are safely 
excreted from the body 21. Their amphiphilic properties allow for stabilization of labile 
proteins 22–24, provide sustained release of encapsulated proteins via surface erosion 
kinetics 23,25–27, and allow for enhanced shelf stability of encapsulated proteins, even at 
elevated temperatures (e.g., 40 °C) 23. Additionally, polyanhydride particles display 
inherent adjuvanticity, demonstrating chemistry-dependent internalization, persistence, 
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and activation of antigen presenting cells in vitro, as well as the ability to prime humoral 
and cell-mediated immune responses in vivo 28,29,38–40,30–37. These properties have enabled 
the study of polyanhydride nanoparticle-based vaccines (i.e., nanovaccines) against 
multiple bacterial and viral pathogens 23,27,35,41,42.  
Previous work from our laboratories demonstrated that encapsulation of F1-V into 
polyanhydride particles maintained F1-V structure and prolonged antigen bioavailability 
22, and a single, intranasal dose of F1-V nanovaccine provided complete protection 
against lethal challenge of Y. pestis for at least 280 days post-immunization (DPI) 35. In 
addition to long-lived protective immunity, it is also important that vaccines induce rapid 
(i.e., ≤ 14 days) protective immunity to counter acute outbreaks of disease. In this regard, 
to our knowledge there are no single dose plague vaccine formulations that can induce 
rapid protective immunity against Y. pestis. Designing next-generation vaccine platforms 
that provide both rapid and long-lived (i.e., > 1 year) immunity against highly lethal 
pathogens will likely require novel approaches, including developing new adjuvants or 
vaccine regimen with combination adjuvants to enhance both rapid and long-lived 
protective immunity. Herein, the design and evaluation of a combination nanovaccine, 
comprising of F1-V-containing polyanhydride nanoparticles and a non-canonical CDG 
CDN adjuvant (containing 2’,5’-3’-5’ phosphate linkages) is described. This nanovaccine 
formulation synergistically combines the adjuvant properties of polyanhydride 
nanoparticles and CDNs to induce rapid immune responses and facilitate the induction of 




Material and Methods 
Materials 
Chemicals used for CPTEG and CPH diacid and polymer synthesis included 1,6-
dibromohexane, triethylene 4-p-hydroxybenzoic acid, and 1-methyl-2-pyrrolidinone, 
purchased from Sigma-Aldrich (St. Louis, MO). Chloroform, petroleum ether, ethyl 
ether, hexanes, sodium hydroxide, toluene, sulfuric acid, acetonitrile, dimethyl 
formamide, acetic anhydride, methylene chloride, pentane, and potassium carbonate were 
purchased from Fisher Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile was purchased 
from Apollo Scientific (Cheshire, UK). Deuterated chloroform used for 1H NMR analysis 
was purchased from Cambridge Isotope Laboratories (Andover, MA). Dithio-RP,RP-
cyclic di-guanosine monophosphate (R,R-Cyclic di-GMP (cdG)) was provided by Aduro 
Biotech (Berkeley, CA). Complete cell culture medium reagents RPMI 1640 and 
penicillin-streptomycin were purchased from Mediatech (Herndon, VA); heat inactivated 
fetal calf serum was purchased from Atlanta Biologicals (Atlanta, GA). Y. pestis, strain 
CO92 (NR-641) and the Y. pestis fusion protein F1-V (NR-4526) were obtained from the 
Biodefense and Emerging Infections Repository (Manassas, VA). 
Polyanhydride synthesis 
CPTEG and CPH diacids were synthesized as previously described 26,33. 20:80 
CPTEG:CPH copolymer synthesis was performed using melt polycondensation 26. 
Copolymer composition and molecular weight were estimated using end group analysis 
of 1H NMR (DXR 500) spectra.  
Nanoparticle synthesis 
10 % (w/w) F1-V-loaded 20:80 CPTEG:CPH nanoparticles were synthesized 
using flash nanoprecipitation, as described previously 28. Briefly, F1-V and 20:80 
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CPTEG:CPH copolymer was dissolved in methylene chloride at 2 mg/mL and 20 
mg/mL, respectively, sonicated at 30 Hz for approximately 30 seconds, and poured into 
pentane chilled to -20 °C at a methylene chloride:pentane ratio of 1:250. Nanoparticles 
were imaged using scanning electron microscopy (SEM; JEOL 840 A, JEOL Ltd., 
Tokyo, Japan), and nanoparticle mean size and size distribution were determined using 
ImageJ (National Institutes of Health, Bethesda, MD). Nanoparticle zeta potential was 
measured using Zetasizer Nano (Malvern Instruments, Worcestershire, UK).  
Protein release and encapsulation efficiency 
To quantify released protein, approximately 2 mg of nanoparticles were 
suspended in 500 μL of PBS, sonicated for 15 seconds, and placed on a shaker plate at 37 
°C. Periodically, 400 μL aliquots of sample supernatant were withdrawn and sample 
volumes were reconstituted with 400 μL of fresh PBS. After 32 days, 40 mM sodium 
hydroxide was used in place of PBS to catalyze the release of any remaining protein. 
Protein released from F1-V-loaded 20:80 CPTEG:CPH nanoparticles was quantified 
using a microbichoninic acid (microBCA) assay (Thermo Fisher Scientific, Waltham, 
MA), and percent by mass of protein released over time was calculated as the cumulative 
protein released from nanoparticles at each time point divided by total mass of protein 
released. To quantify protein encapsulation efficiency, approximately 1 mg of 
nanoparticles was suspended in 500 μL of 40 mM sodium hydroxide solution, sonicated 
for 15 seconds, and placed on a shaker plate at 37 °C. Frequently, 400 μL samples of 
supernatant were withdrawn and sample volumes were reconstituted with 400 μL of 40 
mM sodium hydroxide. Protein released from F1-V-loaded 20:80 CPTEG:CPH 
nanoparticles was quantified using a microBCA assay, and the encapsulation efficiency 
77 
 
was calculated as the sum of the protein released from the nanoparticles divided by the 
initial mass of protein. 
Animals 
Seven to eight-week old female C57BL/6NCrl mice were purchased from Charles 
River (Wilmington, MA). Mice were housed under specific pathogen-free conditions 
where all bedding, caging, water, and feed were sterilized prior to use. All studies were 
conducted with the approval of the Iowa State University Institutional Animal Care and 
Use Committee (IACUC). 
Immunization and serum collection 
Groups comprised of C57BL/6 mice (n = 8-16/group) were immunized 
subcutaneously at the nape of the neck with either of the following: 50 µg F1-V + 35 µg 
CDNs (R,R-CDG, Aduro Biotech), 36-50 µg F1-V encapsulated into 500 µg of 20:80 
CPTEG:CPH nanoparticles, 36-50 µg F1-V encapsulated into 500 µg of 20:80 
CPTEG:CPH nanoparticles + 35 µg CDNs, or saline in a total volume of 200 µL. Blood 
was collected from mice via saphenous vein and serum was separated following 
centrifugation (10,000 rcf for 10 min) at 13, 14, 36, 49, 79, 101, 121, 150, and 178 DPI. 
An additional serum sample was obtained from mice sacrificed for ELISPOT analysis at 
218 DPI via cardiac exsanguination. Serum was stored at -20°C until analysis. 
Bronchoalveolar lavage (BAL) fluid was collected post-euthanization by introducing a 
catheter needle through a small incision made in the trachea and injecting/aspirating 700 
µL of PBS thrice.  
ELISA 
Anti-F1-V antibody titers were determined via ELISA, as previously described 27. 
Briefly, high-binding Costar 590 EIA/RIA microtiter plates (Corning) were coated 
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overnight with 100 µL of a 0.5 µg/mL solution of F1-V at 4 °C. After washing the wells, 
microtiter plates were blocked for two hours with a solution of 2.5% (w/v) powdered 
skim milk dissolved in PBS-Tween with 0.05% Tween 20, pH 7.4, that had been 
incubated for two hours at 56 °C to inactivate any endogenous phosphatase activity. 
Following block, microtiter plates were washed thrice with PBS-T. Serum obtained from 
immunized mice was added at a dilution of 1:200 and serially diluted in PBS-T 
containing 1% (v/v) goat serum. Each sample was tested in duplicate. Following 
incubation overnight at 4°C, plates were washed thrice with PBS-T, after which 
secondary antibody was added at a dilution of 1 µg/mL. Secondary antibodies used in 
these studies were: alkaline phosphatase-conjugated goat anti-mouse IgG heavy and light 
chain, IgG1 and IgG2c (Jackson ImmunoResearch). Plates were incubated for two hours 
at room temperature and then washed three times with PBS-T. To each well, 100 µL of 
alkaline phosphatase substrate (Fisher Scientific, Pittsburgh, PA) was added at a 
concentration of 1 mg/mL dissolved in 50 mM sodium carbonate, 2 mM magnesium 
chloride buffer at pH 9.3 for colorimetric development. Plates were analyzed after 30 min 
using a SpectraMax M3 microplate reader at a wavelength of 405 nm. Titer is reported as 
the reciprocal of serum dilution at which the optical density (OD) value was at most 0.2, 
a conservative endpoint greater than the average OD of saline-mouse serum, at a 1:200 
dilution, plus two standard deviations.  
ELISPOT  
MultiScreen 96-well plates (Millipore Sigma, Billerica, MA) were pretreated with 
35 % ethanol for one minute, washed three times with PBS, and coated overnight at 4 °C 
with 0.5 µg/mL F1-V in PBS. The following day, plates were dumped and blocked with 
complete tissue culture medium consisting of RPMI 1640 (Gibco, Grand Island, NY), 
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10% (v/v) fetal calf serum, 1% (v/v) penicillin-streptomycin, and 1% (v/v) L-glutamine 
for at least two hours at 37 °C. Plates were dumped and single cell suspensions of bone 
marrow or splenic lymphocytes harvested from mice between 214-218 days post-
immunization were added to the plates at 500,000 cells per well and placed in a 37 °C 
incubator for two hours. Plates were then washed three times with PBS, another three 
times with PBS-T, and alkaline phosphatase-conjugated goat anti-mouse IgG (H+L) 
secondary antibody (Jackson ImmunoResearch) was added to the wells at a 1:500 
dilution in 1% (v/v) goat serum PBS-T for two hours at room temperature. Plates were 
washed six times with PBS-T and 25 µL per well of BCIP/NBT liquid substrate 
(Millipore Sigma) was added to the wells and developed for 15 min at room temperature. 
Plates were emptied, the bottoms removed, and gently washed with nanopure water, after 
which they were left to dry completely. Spots were counted using an AID Multispot 
Reader (AID, Strassberg, Germany). AID EliSpot software (Version 6.0) was used for 
data analysis. 
Peptide microarray printing and analysis 
Twenty seven 14- to 17-mer linear peptides (11 amino acid overlaps) spanning the 
full length of F1 antigen and fifty three 15- to 17-mer linear peptides (11 or 12 amino 
acid overlaps) spanning the full length of V antigen, as well as full length proteins F1-V, 
Bacillus anthracis protective antigen (PA), and chicken egg ovalbumin (OVA) were 
printed onto Nexterion Slide AL (Schott, Louisville, KY) using a BioRobotics 
MicroGRID II microarray printer (Genomic Solutions, Inc. Ann Arbor, MI). Peptides and 
proteins were dissolved into DMSO at 10 mg/mL to ensure dissolution, then diluted 10-
fold in water to 1 mg/mL. The solution was diluted to bring the final concentration to 0.5 
mg/mL in 1x print buffer (5% (v/v) DMSO, 137 mM NaCl, 9 mM KOH, 11.3 mM 
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NaH2PO4). The full length F1-V fusion protein was used as a positive control, while PA 
and OVA were used as negative controls. Slides were printed with 16 arrays per slide, 
each array containing 16x16 spots per array, with peptides printed in a serpentine pattern 
in triplicate. Following printing, slides were vacuum sealed and stored at -80 °C until 
further use.  
Microarray slides were warmed to room temperature and then placed on a hot 
plate at 37 °C for 30 min to dry; the slides were then placed immediately in a blocking 
solution consisting of 1 % BSA (w/v) in PBS-T for one hour. Slides were subsequently 
blocked for one hour in 1 % (v/v) goat serum PBS-T, then thrice washed with PBS-T and 
placed into a 16-well incubation chamber (Nexterion IC-16) to separate individual arrays. 
Serum was added at a 1:20 dilution for one hour at room temperature with gentle 
agitation. Slides were washed thrice with PBS-T and biotinylated goat anti-mouse IgG 
(H+L) secondary antibody (Jackson ImmunoResearch) was added to wells at 1:1000 
dilution for one hour at room temperature with gentle agitation. Slides were washed 
thrice with PBS-T. Streptavidin Alexa Fluor 555 conjugate was added to wells at a 
1:1000 dilution for 30 min at room temperature with gentle agitation. Slides were 
removed from incubation chambers, washed thrice with PBS-T, followed by another 
three washes with PBS. Slides were spun dry by centrifugation and read on the Scanarray 
5000 laser scanner (GSI Lumonics, Bedford, MA). 
The scanned images of the microarray slides were analyzed using SoftWorRx 
Tracker v2.8 software (Applied Precision, Inc., Issaquah, WA) to detect and quantify the 
fluorescence of each spot. R (v3.4.1) software was used to calculate the background-
corrected fluorescence of each spot as the mean fluorescence intensity of each spot minus 
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the median background fluorescence intensity surrounding the spot. The mean 
fluorescence intensity for each peptide or protein was calculated as the average of the 
corresponding triplicate background-corrected fluorescence spot values, and a heat map 
was generated based upon the magnitude of individual mouse serum responses to each 
peptide. Saline-treated mouse serum was used as a negative control. 
Challenge 
Y. pestis CO92 (NR-641) was obtained from BEI Resources. Frozen stocks were 
prepared in advance of challenges. Y. pestis was initially grown on brain heart infusion 
(BHI) agar at 28 °C for 72 h; a single colony was isolated and inoculated in BHI broth 
and cultivated for 24 h at 28 °C while shaking at 120 rpm. Glycerol solution was added to 
the broth to bring final glycerol concentration to 5% (v/v). Aliquots were snap frozen and 
stored at -72 °C. Prior to challenge experiments, aliquots of the frozen stock were thawed 
and cultured on tryptic soy agar (TSA) with 1% bovine hemoglobin at 37°C and 5% CO2 
to check viability and CFU enumeration. For challenge experiments, frozen Y. pestis 
stocks were thawed and diluted in room temperature PBS. Groups of C57BL/6 mice 
immunized as described previously were anesthetized with an intraperitoneal injection of 
ketamine/xylazine cocktail and infected intranasally with 5,700, 7,000, or 10,000 CFU 
(14 DPI) or 6500 CFU (218 DPI) of Y. pestis CO92 in a 50 µL volume. Y. pestis bacterial 
suspension was administered intranasally to nares of mice by a micropipette. CFU 
enumeration was performed on infectious inoculum preceding to and following infection 
of the animals to determine infectious dose administered. Animals were checked daily for 
morbidity and mortality over the course of two weeks. All activities were performed in an 
animal biosafety level 3 (ABSL-3) laboratory at Iowa State University with protocols 




Statistical analyses on the ELISA data as well as the survival data were performed 
using the Mantel-Cox log rank test and the one-way analysis of variance (ANOVA) using 
Tukey’s multiple comparisons test. Statistical significance in microarray serum responses 
to each peptide between vaccinated groups of animals was evaluated using Student’s t 
test. A p-value ≤ 0.05 was considered to be statistically significant. All analyses were 
performed using GraphPad Prism v. 7.0 (GraphPad, La Jolla, CA). 
 
Results 
F1-V nanovaccine characterization 
Following synthesis, the F1-V nanovaccine was characterized for size 
distribution, surface charge, release kinetics, and encapsulation efficiency of encapsulated 
F1-V. The size of the F1-V nanovaccine was consistent with previous work 35, with a 
mean diameter of 228 ± 78 nm and a polydispersity index of 0.12, indicating a narrow 
size distribution (Figure 3.1A and 3.1B). Zeta potential measurements of the F1-V 
nanovaccine demonstrated a negative surface charge, with zeta potentials of -34.8 ± 1.4 
mV. In order to provide sufficient antigen to induce a robust immune response for rapid 
protection, while also sustaining the release of antigen to induce long-lived protective 
immunity, this nanoparticle formulation was designed with a 10% w/w loading of F1-V 
providing a biphasic release profile that was characterized by an initial burst of 
approximately 75% of the protein released within the first 24 h, followed by slow zero 
order release over more than two months (Figure 3.1C). The encapsulation efficiency of 




Figure 3.1 Characterization of F1-V Nanovaccine. A) Representative scanning electron 
photomicrograph of F1-V nanovaccine (scale bar = 3 µm). B) Nanoparticle size 
distribution of the F1-V nanovaccine (228 ± 78 nm), determined via ImageJ analysis. C) 
Cumulative in vitro F1-V release profile from the nanovaccine. Nanoparticles were 
suspended in PBS (pH 7.4) and released protein was quantified via a microBCA assay. 
 
Combination nanovaccine induces rapid protective immunity  
In order to assess the potential of CDNs and nanovaccines to rapidly stimulate 
protective immunity, C57BL/6 mice (n=12-16 per group) were immunized 
subcutaneously with a single dose of one of the following vaccine formulations: i) 
soluble F1-V adjuvanted with CDNs (CDN Vaccine), ii) F1-V encapsulated into 20:80 
CPTEG:CPH nanoparticles (Nanovaccine), iii) F1-V encapsulated into 20:80 
CPTEG:CPH nanoparticles co-adjuvanted with CDNs (Combination Nanovaccine), or iv) 
saline alone. Blood samples were collected from immunized animals at 13 DPI (Figure 
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3.2A, C, E). Anti-F1-V total IgG antibody titers from CDN Vaccine- and Combination 
Nanovaccine-immunized animals evaluated at 13 DPI were similar in magnitude and 
showed significantly (p ≤ 0.0001) higher titers than sera from animals immunized with 
the Nanovaccine alone.  
Mice were challenged intranasally 14 DPI with escalating lethal doses of Y. pestis 
CO92 in separate studies and survival was assessed over a period of two weeks (Figure 
3.2B, D, F). All naïve (i.e., saline-treated) mice succumbed to infection within four days 
of challenge, while all Nanovaccine-immunized mice succumbed over a period of eight 
days following challenge. In contrast, immunization with Combination Nanovaccine 
yielded 100% protection against all challenge doses, while immunization with CDN 
Vaccine showed decreasing levels of efficacy with increasing challenge doses. Both 
Combination Nanovaccine and CDN Vaccine immunization regimens provided 
significantly (p ≤ 0.0001) superior protection when compared to Nanovaccine or saline 
regimens for challenges at 5,700, 7,000, and 10,000 CFU. Immunization with 
Combination Nanovaccine formulation provided significantly better protection (p ≤ 







Figure 3.2 Combination Nanovaccine provides rapid protective immunity against lethal Y. pestis challenge. Groups of C57BL/6 mice 
(n=12-16 per group) were immunized subcutaneously with the following groups: F1-V + CDNs (CDN Vaccine), F1-V encapsulated 
into nanoparticles (Nanovaccine), F1-V encapsulated into nanoparticles + CDNs (Combination Nanovaccine) or saline. (A,C,E) 
Serum was collected at 13 DPI and evaluated via ELISA for total anti-F1-V IgG antibody titers. The dashed line represents anti-F1-V 
IgG (H+L) antibody titers from saline-treated mice as a negative control. * p ≤ 0.0001 compared to Nanovaccine and saline. Mice 
86 
 
were challenged at 14 DPI with (B) 5,700 CFU, (D) 7,000 CFU, or (F) 10,000 CFU Y. 
pestis CO92 and survival was monitored for two weeks post-challenge. * p ≤ 0.0001 
compared to saline-treated mice. + p ≤ 0.0001 compared to Nanovaccine-immunized 
mice. # p ≤ 0.05 compared to CDN Vaccine-immunized mice. 
Combination nanovaccine enhances long-lived protective immunity 
Previous work from our laboratories has shown the potential for a single dose 
nanovaccine, consisting of a soluble bolus of F1-V and F1-V containing nanoparticles, to 
enhance long-lived antibody responses for at least 280 DPI and provide protective 
immunity 27,35. To evaluate the potential for a single dose of the CDN vaccine and the 
two nanovaccines (with no soluble F1-V bolus) to induce long-lived protective immunity, 
separate groups of C57BL/6 mice (n=8-12 per group) were immunized subcutaneously 
with the same formulations as above and anti-F1-V total IgG titers were evaluated 
between 14-218 DPI (Figure 3.3A and Figure 3.4). At all timepoints, sera from both 
Combination Nanovaccine-immunized and CDN Vaccine-immunized mice showed 
comparable and significantly (p ≤ 0.0001) higher titers than sera from Nanovaccine-
immunized mice. Serum was analyzed at 14, 79 and 178 DPI for presence of class-
switched anti-F1-V IgG1, IgG2c and IgG3 antibodies (Figure 3.5). All vaccination 
regimens produced detectable IgG1 at 14 and 79 DPI significant (p ≤ 0.0001) over 
background, with Combination Nanovaccine and CDN Vaccine groups also showing 
significant (p ≤ 0.04) responses at 178 DPI (Figure 3.5A). Additionally, Combination 
Nanovaccine- and CDN Vaccine-immunized animals showed significantly (p ≤ 0.05) 
higher IgG1 titers compared to Nanovaccine-immunized mice at 79 DPI. Sera from 
animals immunized with both Combination Nanovaccine and CDN Vaccine exhibited 
significantly (p ≤ 0.0001) higher IgG2c antibody titers at all time points, and IgG3 at 14 
DPI, compared to sera from Nanovaccine-immunized and Saline-treated mice (Figure 
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3.5B and C). Lastly, a subset of mice (n=2-4) were euthanized 214-218 DPI and 
bronchoalveolar lavage (BAL) fluid was collected for evaluation of anti-F1-V lung IgG 
(Figure 3.6) and IgA. The BAL fluid recovered from the animals immunized with 
Combination Nanovaccine and CDN Vaccine was found to have significantly (p ≤ 0.05) 
higher total anti-F1-V IgG compared to that from animals immunized with Nanovaccine 
or treated with Saline. No IgA was detected in the BAL fluid (data not shown).  
Mice were challenged intranasally at 182 DPI with a lethal dose of Y. pestis CO92 
(6500 CFU) and survival was assessed over a two-week period (Figure 3.3B). All naïve 
mice succumbed to infection within three days of challenge. However, all Nanovaccine-
immunized mice succumbed over a period of seven days following challenge that was 
significantly (p ≤ 0.05) prolonged compared to naïve mice. Both the Combination 
Nanovaccine and CDN Vaccine immunization regimens induced superior protection (p ≤ 
0.01) when compared to the Nanovaccine or saline treated mice. Specifically, 
immunization with the Combination Nanovaccine provided 75% protection from lethal 






Figure 3.3 Combination Nanovaccine provides long-lived protective immunity against 
lethal Y. pestis challenge. Groups of C57BL/6 mice (n=12-16 per group) were immunized 
subcutaneously with the following treatments: F1-V + CDNs (CDN Vaccine), F1-V 
encapsulated into nanoparticles (Nanovaccine), F1-V encapsulated into nanoparticles + 
CDNs (Combination Nanovaccine) or saline. (A) Serum samples were collected at 14, 
36, 79, 121, and 178 DPI and analyzed for total anti-F1-V IgG (H+L) antibodies via 
ELISA. The dashed line represents the background anti-F1-V IgG (H+L) antibody 
response from naive mice.  # p ≤ 0.05 compared to CDN Vaccine. * p ≤ 0.0001 compared 
to Nanovaccine-immunized and saline-treated mice. (B) Mice were challenged at 182 
DPI with 6500 CFU Y. pestis CO92 and survival was monitored for two weeks post-
challenge. # p ≤ 0.01 compared to Nanovaccine-immunized mice. * p ≤ 0.05 compared to 





Figure 3.4. Combination Nanovaccine provides long-lived antibody responses to F1-V. 
Groups of C57BL/6 mice (n=12-16 per group) were immunized subcutaneously with the 
following groups: 50 µg F1-V + 35 µg CDNs (CDN Vaccine), 36 µg F1-V encapsulated 
into 500 µg nanoparticles (Nanovaccine), 36 µg F1-V encapsulated into 500 µg 
nanoparticles + 35 µg CDNs (Combination Nanovaccine) or Saline. Serum samples were 
collected at 14, 36, 49, 79, 101, 121, 150, 178, and 218 DPI and analyzed for total anti-
F1-V IgG (H+L) antibodies via ELISA. # p ≤ 0.05 compared to CDN Vaccine. * p ≤ 





Figure 3.5 Combination Nanovaccine induces class-switched antibody responses to F1-V. 
Groups of C57BL/6 mice (n=12-16 per group) were immunized subcutaneously with the 
following groups: 50 µg F1-V + 35 µg CDNs (CDN Vaccine), 36 µg F1-V encapsulated 
into 500 µg nanoparticles (Nanovaccine), 36 µg F1-V encapsulated into 500 µg 
nanoparticles + 35 µg CDNs (Combination Nanovaccine) or Saline. Serum samples were 
collected at 14, 79, and 178 DPI and analyzed for anti-F1-V IgG1, IgG2c, and IgG3 
antibodies via ELISA. * p ≤ 0.0001 compared to saline-treated mice. # p ≤ 0.05 




Figure 3.6 Combination Nanovaccine induces long-lived antibody responses in BAL fluid 
against F1-V. Groups of C57BL/6 mice (n=12-16 per group) were immunized 
subcutaneously with the following groups: 50 µg F1-V + 35 µg CDNs (CDN Vaccine), 
36 µg F1-V encapsulated into 500 µg nanoparticles (Nanovaccine), 36 µg F1-V 
encapsulated into 500 µg nanoparticles + 35 µg CDNs (Combination Nanovaccine) or 
Saline. BAL fluid was collected 213-218 DPI and assessed for total anti-F1-V IgG (H+L) 
antibodies via ELISA. * p ≤ 0.0001 compared to Nanovaccine-immunized and saline-
treated mice. 
 
Combination nanovaccine provides broad antibody IgG recognition to F1-V linear 
epitopes 
A linearly overlapping peptide array was performed to identify F1-V-specific IgG 
(H+L) antibodies in serum, collected from mice immunized with either CDN Vaccine, 
Nanovaccine, or Combination Nanovaccine and naïve controls at 14, 79, and 178 DPI, 
reactive to 14- to 17-mer linear peptides spanning the full length of F1 antigen, 15- to 17-
mer linear peptides spanning the full length of V antigen, and F1-V fusion protein (Figure 
3.7). The antibody response to F1-V and all linear epitopes in mouse serum collected at 
14 DPI was noticeably lower than at 79 and 178 DPI. In addition, naïve mouse serum did 
not bind appreciably to either F1-V, or any F1 or V peptides, at any time point evaluated.  
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Serum from CDN Vaccine- and Combination Nanovaccine-immunized animals 
elicited antibodies that bound multiple linear peptides from F1 and V antigens across all 
time points, with responses observed to peptides F1-3, F11, and V45-46 at all time points 
evaluated (p < 0.05 compared to non-vaccinated mice). At 178 DPI, serum antibody from 
both CDN Vaccine- and Combination Nanovaccine-immunized animals continued to 
react with peptides F9, V18, V32, and V44 (Fig. 3.7, blue arrows). Serum from mice 
immunized with Nanovaccine possessed fewer F1- and V-peptide specific antibodies 
compared to CDN Vaccine- and Combination Nanovaccine-immunized animals, 
however, responses to peptides F1 and V44-45 were observed at all time points 
evaluated. 
 
Combination nanovaccine induces long-lived plasma cells  
As anti-F1-V-specific serum antibody was found to persist for at least 218 days, 
ELISPOT analysis was performed on cells harvested from spleen and bone marrow at 
214-218 DPI to demonstrate the presence of the long-lived antibody secreting cells 
(ASCs). Analysis of bone marrow revealed a significantly (p < 0.05) higher number of 
F1-V-specific ASCs in CDN Vaccine- and Combination Nanovaccine-immunized mice 







Figure 3.7 Combination Nanovaccine and CDN Vaccine provide broad antibody responses to potentially protective linear epitopes. 
Serum samples collected from C57BL/6 mice (n=12-16 per group) immunized with either saline, CDN Nanovaccine, Nanovaccine, or 
Combination Nanovaccine 14, 79, and 178 DPI was analyzed for total anti-F1-V IgG antibodies against twenty-seven 14- to 17-mer 
linear peptides (11 amino acid overlaps) from the F1 antigen and fifty-three 15- to 17-mer linear peptides (11 or 12 amino acid 
overlaps) from the V antigen. The peptides were covalently bound to microarray slides as described in Materials and Methods. Each 
row corresponds to a specific peptide, the top row representing peptide F1 and the proceeding downward rows corresponding to each 
following linear peptide incrementally through peptide V53. Each column represents responses from a single mouse. The mean 
fluorescence intensity of serum responses to each peptide is represented by a range of color from white (no response) to purple 
(maximum response). The full-length F1-V fusion protein was used as a positive control, and Bacillus anthracis protective antigen 
(PA) and chicken egg ovalbumin (OVA) were used as negative controls. Black arrows indicate significance (p < 0.05) of Combination 
Nanovaccine and CDN Vaccine serum compared to naïve serum at all time points evaluated. Blue arrows indicate significance (p < 
0.05) of Combination Nanovaccine and CDN Vaccine serum compared to naïve serum at 178 DPI. 
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There was no difference in the number of ASCs in the bone marrow of 
Nanovaccine-immunized mice compared to non-vaccinated mice. Additionally, there was 
no difference in the number of ASCs detected in the spleens harvested from immunized 
mice versus naïve mice at 218 DPI (Figure 3.8B). Analysis of ASC-derived antibody IgG 
subclass expression revealed a trend of a greater number of F1-V-specific IgG2c ASCs 
present in the bone marrow of CDN Vaccine- and Combination Nanovaccine-immunized 
mice compared to non-vaccinated mice 218 DPI; however, this difference was not 
statistically significant (Figure 3.9). There was no difference in the number of F1-V-
specific IgG2c ASCs in the spleen 218 DPI, nor was there a difference in the number of 
F1-V-specific IgG1 ASCs between all vaccine groups in either spleen or bone marrow.  
 
Figure 3.8 Long-lived antibody responses to F1-V originate from long-lived plasma cells 
in the bone marrow. Bone marrow and splenic lymphocytes were harvested at 213-218 
DPI from groups (n=3-4/group) of C57BL/6 mice immunized with CDN Vaccine, 
Nanovaccine, Combination Nanovaccine regimens, or treated with saline, and were 
analyzed via ELISPOT for the number of F1-V-specific antibody secreting cells. Data 
represent the number of F1-V-specific antibody secreting cells per 500,000 bone marrow 
or spleen cells from individual mice from one experiment. * p ≤ 0.02 compared to saline-




Figure 3.9 Long-lived anti-F1-V IgG1 and IgG2c antibody secreting cell responses in 
bone marrow and spleen. Groups of C57BL/6 mice (n=12-16 per group) were immunized 
subcutaneously with the following treatments: F1-V + CDNs (CDN Vaccine), F1-V 
encapsulated into nanoparticles (Nanovaccine), F1-V encapsulated into nanoparticles + 
CDNs (Combination Nanovaccine) or saline. Bone marrow and spleen lymphocytes were 
harvested at 213-218 DPI from groups (n=3-4/group) of mice and were analyzed via 
ELISPOT for the number of F1-V-specific IgG1 and IgG2c antibody secreting cells from 
spleen (panels A and C) or bone marrow (panels B and D). Data points represent the 
number of F1-V-specific antibody secreting cells per 500,000 bone marrow or spleen 
cells from individual mice from one experiment. 
Discussion 
With increasing concern of biological weaponization, it is of paramount 
importance to enhance preparedness with biodefense vaccines that can induce both rapid 
and long-lived protective immunity. To date, there is no FDA-approved vaccine against 
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Y. pestis, a weaponizable pathogen. An efficacious, single-dose vaccine would be vitally 
important to induce rapid and long-lived protective immunity both in the critical window 
of time immediately following an exposure event as well as for military personnel against 
potential exposure before deployment. Previous work on pneumonic plague vaccines 
from other laboratories has shown some success using aluminum hydroxide-based and 
TLR-targeting adjuvants; however, many of these studies required prime-boost 
vaccination and none demonstrated the ability to induce protective immunity within 14 
DPI 10,27,43,44.  
The goal of this work was to incorporate the benefits of two novel adjuvants (i.e., 
CDNs and polyanhydride nanoparticles) in order to design a single-dose, combination 
vaccine that would provide both rapid and long-lived immunity. Previously, it was shown 
that a single dose of intranasally administered nanovaccine containing 40 µg soluble F1-
V antigen and 10 µg F1-V encapsulated into polyanhydride nanoparticles provided 100 
% protection for at least 280 DPI 35. Additionally, it was previously demonstrated that 
intranasally administered 20:80 CPTEG:CPH nanoparticles elicited demonstrable F1-V-
specific antibody titers as early as 14 DPI 28. Motivated by these studies, a combination 
nanovaccine including R,R-CDG CDNs and F1-V-containing 20:80 CPTEG:CPH 
nanoparticles was designed with rapid release of antigen (Figure 3.1) in order to initiate 
the adaptive immune response. This current work highlights the potent 
immunostimulatory properties of polyanhydride nanoparticle- and CDN-based 
combination adjuvants, which individually could not provide rapid protection when the 
challenge inoculum contained ≥ 7000 CFU Y. pestis; however, when administered 
together, rapid and complete protection against all three lethal doses of Y. pestis was 
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achieved (Figure 3.2). The results indicate that while the CDN vaccine induced a similar 
anti-F1-V antibody titer as did the Combination Nanovaccine formulation, only the latter 
formulation induced rapid protection (14 DPI) against all three challenge doses of Y. 
pestis CO92, suggesting a qualitative difference in the immune response induced by the 
Combination Nanovaccine formulation. Therefore, it is possible that polyanhydride 
nanoparticles modulated immune responses beyond humoral immunity. Indeed, previous 
reports have demonstrated that vaccinated B cell-deficient µMT mice were protected 
from lethal challenge with the KimD27 strain of Y. pestis52 and that blocking IFN-ɣ and 
TNF-α in F1-V-vaccinated C57BL/6 mice resulted in loss of protection against Y. pestis 
CO9253. As previously mentioned, polyanhydride particles display inherent adjuvanticity 
demonstrating the ability to prime humoral and cell-mediated immune responses in vivo 
28,29,38–40,54,30–37; therefore, the nanovaccine regimen may be activating cellular immune 
responses that contribute to the protection at higher challenge doses of Y. pestis CO92. 
The focus on the importance of serum antibody to the immunity induced by 
plague vaccines is based largely on the following: 1) human patients infected with Y. 
pestis demonstrate long-lived antibody responses to F1 and V antigens with little to no 
demonstrable T cell responses 45, 2) monoclonal antibodies passively transferred to mice 
have been shown to be protective against lethal challenge 7–9, 3) direct neutralization of 
LcrV has been shown to be necessary to prevent Yop translocation into macrophages in 
vitro 6, 4) murine challenge models have suggested that anti-F1 IgG1 antibody titer 
correlates with survival 5, and 5) mucosal and serum anti-V antigen antibodies are the 
best correlates for survival against pneumonic plague in mice 46. Regardless of the route 
of immunization, the induction or presence of neutralizing antibodies in the lungs is 
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likely critical for protection against Y. pestis; and, it has been demonstrated that 
intratracheally administered monoclonal antibody (mAb) 7.3 protected mice against 
lethal intranasal challenge 47 48,49. The results herein support this notion, as high IgG 
levels in peripheral blood and BAL fluid were observed 218 DPI (Supplementary Figures 
3.1 and 3.3) following a single, subcutaneous administration of the Combination 
Nanovaccine.  
Elevated antibody responses observed in this work are in agreement with 
previously reported studies that demonstrated that the use of CDG as an adjuvant 
enhances antibody responses compared to traditional adjuvants 16,17,50,51. In this work, the 
resultant antibody responses induced by both the Combination Nanovaccine and CDN 
Vaccine were characterized by high affinity, class-switched F1-V-specific IgG1 and 
IgG2c by 14 DPI (Figure 3.2 and Figure 3.4). The antibody response was also 
characterized by a stable F1-V-specific antibody response over 218 DPI that was 
accompanied by evidence of F1-V-specific long-lived plasma cells in the bone marrow 
(Figure 3.4 & Figure 3.8).  
Using microarray technology, potential protective immunodominant peptide were 
identified that were consistent with previously published reports. Xiao et al. identified 
monoclonal antibodies (mAbs) which bound to peptides F1-2, V19-20, and V28 and 
together conferred protection against lethal challenge 8. In the current study, responses to 
F1-3 were observed in sera from immunized mice at all time points. It has also been 
reported that a neutralizing mAb BA5 binds amino acids 196-225, corresponding to 
peptides V31-39, and protects mice against systemic challenge 55. Consistent with this 
study, serum antibody recognized V32 suggesting that the Combination Nanovaccine 
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elicited antibodies with potentially similar neutralizing capacity as mAb BA5. Khan et al. 
previously characterized peptides ‘b’ (a.a. 46-60) and ‘g’ (a.a. 256-270) as B cell 
epitopes56. Similar antibody responses were observed in this study to peptides F9 (a.a. 49-
65) and V44-46 (a.a. 258-286). Interestingly, there are no previous reports of antibody 
recognition of peptide F11 (a.a. 61-77) or V18 (a.a. 102-118), and, therefore, these 
regions may be of interest for further research. Together, these results suggest that both 
CDN Vaccine and Combination Nanovaccine elicited a polyclonal antibody responses 
that recognized multiple linear epitopes.   
Encapsulation of antigen into polyanhydride nanoparticles can provide many 
beneficial aspects for labile proteins including maintenance of protein structure, and 
adjuvant activity for multiple vaccine antigens 23,57–59, including F1-V 22. The surface 
eroding characteristics of these polymers enables chemistry-dependent release kinetics of 
antigen providing for single-dose (i.e., no booster) vaccination 27,35,41. Previously, 
polyanhydride nanoparticles have shown the ability to adjuvant pneumococcal surface 
protein A (PspA) resulting in the induction of complete protection of mice from a lethal 
challenge of S. pneumoniae that was comparable to that induced by alum-adjuvanted 
PspA with markedly less injection site reactogenicity 19,41. In addition to the adjuvanticity 
of the polyanhydrides, previous reports have demonstrated that protein structure and 
functional activity of the labile recombinant protective antigen from Bacillus anthracis 
was maintained upon encapsulation and release from polyanhydride nanoparticles after 
storage for at least four months at temperatures up to 40 °C 23. Consequently, 
encapsulation of proteins into polyanhydride nanoparticles has the capability to both 
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enhance immune outcomes and provide extended shelf storage, both of which may be 
beneficial with respect to stockpiling biodefense vaccines such as plague vaccines. 
In summary, these results indicate that the Combination Nanovaccine is a 
promising vaccine candidate against Y. pestis based on its ability to induce both rapid and 
long-lived protective immunity. Immune responses to F1-V were characterized by long-
lived high antibody titers, increased breadth of antibody responses to a broader array of 
epitopes, and induction of long-lived plasma cells in the bone marrow for at least 218 
DPI. With the ability to enhance immune responses to F1-V and potential for enhance 
shelf stability of labile proteins, the Combination Nanovaccine shows promise as a next-
generation vaccine platform against weaponized Y. pestis. 
Acknowledgements 
The authors acknowledge financial support from NIH-NIAID (R01 AI111466) 
and the Nanovaccine Institute. The authors thank Drs. David Kanne, Chudi Ndubaku, and 
Thomas Dubensky Jr at Aduro Biotech for providing the cdG used in the immunization 
experiments, as well as Dr. Chris Minion at Iowa State University for providing the 
BioRobotics MicroGRID II microarray printer used for printing microarray slides. The 
authors also acknowledge Dr. Thomas Waldschmidt at the University of Iowa for his 
guidance in ELISPOT assay development. The authors would also like to thank Min 
Zhang at Iowa State University for assistance with the statistical analyses. B.N. 
acknowledges the support of the Vlasta Klima Balloun Faculty Chair. 
Author Contributions 
DW-M and SK performed the experiments and analyzed the data. ACP and RJD 
helped with the development of the microarray experiments and data analysis. NPB and 
101 
 
BHB performed the challenge studies and analyzed the data. MW, BN, DW-M, and SK 
designed the experimental plan. All authors participated in the writing of the manuscript. 
Conflict of Interest Statement 
The authors declare that the research was conducted in the absence of any 
commercial or financial relationships that could be construed as a potential conflict of 
interest.  
References 
1. Pechous, R. D., Sivaraman, V., Stasulli, N. M. & Goldman, W. E. Pneumonic 
Plague: The Darker Side of Yersinia Pestis. Trends Microbiol. 24, 190–197 
(2016). 
2. Riedel, S. Plague: from natural disease to bioterrorism. Proc. (Bayl. Univ. Med. 
Cent). 18, 116–124 (2005). 
3. Ke, Y., Chen, Z. & Yang, R. Yersinia Pestis: mechanisms of entry into and 
resistance to the host cell. Front. Cell. Infect. Microbiol. 3, (2013). 
4. Inglesby, T. V et al. Plague as a biological weapon: medical and public health 
management. JAMA 283, 2281–2290 (2000). 
5. Williamson, E. D. et al. An IgG1 titre to the F1 and V antigens correlates with 
protection against plague in the mouse model. Clin. Exp. Immunol. 116, 107–114 
(1999). 
6. Ivanov, M. I., Hill, J. & Bliska, J. B. Direct neutralization of type III effector 
translocation by the variable region of a monoclonal antibody to Yersinia Pestis 
LcrV. Clin. Vaccine Immunol. 21, 667–673 (2014). 
7. Hill, J., Leary, S. E. C., Griffin, K. F., Williamson, E. D. & Titball, R. W. Regions 
of Yersinia pestis V antigen that contribute to protection against plague identified 
by passive and active immunization. Infect. Immun. 65, 4476–82 (1997). 
8. Xiao, X. et al. Human anti-plague monoclonal antibodies protect mice from 
Yersinia pestis in a bubonic plague model. PLoS One 5, 1–12 (2010). 
9. Hill, J. et al. Synergistic protection of mice against plague with monoclonal 




10. Heath, D. G. et al. Protection against experimental bubonic and pneumonic plague 
by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16, 1131–
7 (1998). 
11. Quenee, L. E., Ciletti, N. A., Elli, D., Hermanas, T. M. & Schneewind, O. 
Prevention of pneumonic plague in mice, rats, guinea pigs and non-human 
primates with clinical grade rV10, rV10-2 or F1-V vaccines. Vaccine 29, 6572–
6583 (2011). 
12. Ma, Z. & Damania, B. The cGAS-STING Defense Pathway and Its Counteraction 
by Viruses. Cell Host Microbe 19, 150–158 (2016). 
13. Danilchanka, O. & Mekalanos, J. J. Cyclic dinucleotides and the innate immune 
response. Cell 154, 962–70 (2013). 
14. Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that 
facilitates innate immune signalling. Nature 455, 674–678 (2008). 
15. Jenal, U., Reinders, A. & Lori, C. Cyclic di-GMP: Second messenger 
extraordinaire. Nat. Rev. Microbiol. 15, 271–284 (2017). 
16. Ebensen, T. et al. The bacterial second messenger cyclic diGMP exhibits potent 
adjuvant properties. Vaccine 25, 1464–1469 (2007). 
17. Hu, D.-L. et al. c-di-GMP as a vaccine adjuvant enhances protection against 
systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 
27, 4867–4873 (2009). 
18. Narasimhan, B., Goodman, J. T. & Vela Ramirez, J. E. Rational Design of 
Targeted Next-Generation Carriers for Drug and Vaccine Delivery. 18, 25–49 
(2016). 
19. Huntimer, L. et al. Evaluation of Biocompatibility and Administration Site 
Reactogenicity of Polyanhydride-Particle-Based Platform for Vaccine Delivery. 
Adv. Healthc. Mater. 2, 369–378 (2013). 
20. Vela-Ramirez, J. E. et al. Safety and Biocompatibility of Carbohydrate-
Functionalized Polyanhydride Nanoparticles. AAPS J. 17, 256–267 (2015). 
21. Kumar, N., Langer, R. S. & Domb, A. J. Polyanhydrides: an overview. Adv. Drug 
Deliv. Rev. 54, 889–910 (2002). 
22. Carrillo-Conde, B. et al. Encapsulation into amphiphilic polyanhydride 




23. Petersen, L. K., Phanse, Y., Ramer-Tait,  a. E., Wannemuehler, M. J. & 
Narasimhan, B. Amphiphilic polyanhydride nanoparticles stabilize bacillus 
anthracis protective antigen. Mol. Pharm. 9, 874–882 (2012). 
24. Vela Ramirez, J. E. et al. Carbohydrate-functionalized nanovaccines preserve 
HIV-1 antigen stability and activate antigen presenting cells. J. Biomater. Sci. 
Polym. Ed. 25, 1387–1406 (2014). 
25. Huntimer, L. et al. Single immunization with a suboptimal antigen dose 
encapsulated into polyanhydride microparticles promotes high titer and avid 
antibody responses. J Biomed Mater Res B Appl Biomater 101, 91–98 (2013). 
26. Torres, M. P., Vogel, B. M., Narasimhan, B. & Mallapragada, S. K. Synthesis and 
characterization of novel polyanhydrides with tailored erosion mechanisms. J. 
Biomed. Mater. Res. - Part A 76, 102–110 (2006). 
27. Ulery, B. D. et al. Design of a protective single-dose intranasal nanoparticle-based 
vaccine platform for respiratory infectious diseases. PLoS One 6, 1–8 (2011). 
28. Haughney, S. L., Ross, K. A., Boggiatto, P. M., Wannemuehler, M. J. & 
Narasimhan, B. Effect of nanovaccine chemistry on humoral immune response 
kinetics and maturation. Nanoscale 6, 13770–13778 (2014). 
29. Kipper, M. J., Shen, E., Determan, A. & Narasimhan, B. Design of an injectable 
system based on bioerodible polyanhydride microspheres for sustained drug 
delivery. Biomaterials 23, 4405–4412 (2002). 
30. Petersen, L. K. et al. Activation of innate immune responses in a pathogen-
mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. 
Biomaterials 32, 6815–6822 (2011). 
31. Torres, M. P. et al. Polyanhydride microparticles enhance dendritic cell antigen 
presentation and activation. Acta Biomater. 7, 2857–2864 (2011). 
32. Petersen, L. K., Xue, L., Wannemuehler, M. J., Rajan, K. & Narasimhan, B. The 
simultaneous effect of polymer chemistry and device geometry on the in vitro 
activation of murine dendritic cells. Biomaterials 30, 5131–5142 (2009). 
33. Kipper, M. J., Wilson, J. H., Wannemuehler, M. J. & Narasimhan, B. Single dose 
vaccine based on biodegradable polyanhydride microspheres can modulate 
immune response mechanism. J. Biomed. Mater. Res. - Part A 76, 798–810 
(2006). 
34. Ulery, B. D. et al. Polymer chemistry influences monocytic uptake of 
polyanhydride nanospheres. Pharm. Res. 26, 683–690 (2009). 
35. Ulery, B. D. et al. Rational design of pathogen-mimicking amphiphilic materials 
as nanoadjuvants. Sci. Rep. 1, 198 (2011). 
104 
 
36. Goodman, J. T. et al. Nanoparticle chemistry and functionalization differentially 
regulates dendritic cell-nanoparticle interactions and triggers dendritic cell 
maturation. Part. Part. Syst. Charact. 31, 1269–1280 (2014). 
37. Phanse, Y. et al. Functionalization of polyanhydride microparticles with di-
mannose influences uptake by and intracellular fate within dendritic cells. Acta 
Biomater. 9, 8902–8909 (2013). 
38. Carrillo-Conde, B. R., Ramer-Tait, A. E., Wannemuehler, M. J. & Narasimhan, B. 
Chemistry-dependent adsorption of serum proteins onto polyanhydride 
microparticles differentially influences dendritic cell uptake and activation. Acta 
Biomater. 8, 3618–28 (2012). 
39. Chavez-Santoscoy, A. V. et al. Tailoring the immune response by targeting C-type 
lectin receptors on alveolar macrophages using “pathogen-like” amphiphilic 
polyanhydride nanoparticles. Biomaterials 33, 4762–4772 (2012). 
40. Carrillo-Conde, B. et al. Mannose-functionalized ‘pathogen-like’ polyanhydride 
nanoparticles target C-type lectin receptors on dendritic cells. Mol. Pharm. 8, 
1877–1886 (2011). 
41. Wagner-Muñiz, D. A., Haughney, S. L., Kelly, S. M., Wannemuehler, M. J. & 
Narasimhan, B. Room Temperature Stable PspA-Based Nanovaccine Induces 
Protective Immunity. Front. Immunol. 9, (2018). 
42. Ross, K. et al. Combination Nanovaccine Demonstrates Synergistic Enhancement 
in Efficacy against Influenza. ACS Biomater. Sci. Eng. 2, 368–374 (2016). 
43. Tao, P. et al. A bivalent anthrax-plague vaccine that can protect against two Tier-1 
bioterror pathogens, Bacillus anthracis and Yersinia Pestis. Front. Immunol. 8, 
(2017). 
44. Mizel, S. B. et al. Flagellin-F1-V fusion protein is an effective plague vaccine in 
mice and two species of nonhuman primates. Clin. Vaccine Immunol. 16, 21–28 
(2009). 
45. Li, B. et al. Humoral and cellular immune responses to Yersinia Pestis infection in 
long-term recovered plague patients. Clin. Vaccine Immunol. 19, 228–234 (2012). 
46. Reed, D. S. & Martinez, M. J. Respiratory immunity is an important component of 
protection elicited by subunit vaccination against pneumonic plague. Vaccine 24, 
2283–2289 (2006). 
47. Hill, J. et al. Administration of antibody to the lung protects mice against 
pneumonic plague. Infect. Immun. 74, 3068–70 (2006). 
105 
 
48. Glynn, A., Freytag, L. C. & Clements, J. D. Effect of homologous and 
heterologous prime-boost on the immune response to recombinant plague antigens. 
Vaccine 23, 1957–1965 (2005). 
49. Uddowla, S., Freytag, L. C. & Clements, J. D. Effect of adjuvants and route of 
immunizations on the immune response to recombinant plague antigens. Vaccine 
25, 7984–7993 (2007). 
50. Blaauboer, S. M. et al. The mucosal adjuvant cyclic di-GMP enhances antigen 
uptake and selectively activates pinocytosis-efficient cells in vivo. Elife 2015, 1–
25 (2015). 
51. Karaolis, D. K. R. et al. Bacterial c-di-GMP is an immunostimulatory molecule. J. 
Immunol. 178, 2171–2181 (2007). 
52. Parent, M. A. et al. Cell-Mediated Protection against Pulmonary Yersinia Pestis 
Infection. Infect. Immun. 73, 7304–7310 (2005). 
53. Lin, J. S. et al. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in 
mouse models of fully virulent pneumonic plague. Vaccine 29, 357–362 (2010). 
54. Huntimer, L. M. et al. Polyanhydride nanovaccine platform enhances antigen-
specific cytotoxic T cell responses. Technology 02, 171–175 (2014). 
55. Quenee, L. E. et al. Amino acid residues 196–225 of LcrV represent a plague 
protective epitope. doi:10.1016/j.vaccine.2009.11.076 
56. Khan, A. A., Babu, J. P., Gupta, G. & Rao, D. N. Identifying B and T cell epitopes 
and studying humoral, mucosal and cellular immune responses of peptides derived 
from V antigen of Yersinia Pestis. Vaccine 26, 316–332 (2008). 
57. Determan, A. S., Graham, J. R., Pfeiffer, K. a & Narasimhan, B. The role of 
microsphere fabrication methods on the stability and release kinetics of ovalbumin 
encapsulated in polyanhydride microspheres. J. Microencapsul. 23, 832–43 
(2006). 
58. Ross, K. A. et al. Hemagglutinin-based polyanhydride nanovaccines against H5N1 
infuenza elicit protective virus neutralizing titers and cell-mediated immunity. Int. 
J. Nanomedicine 10, 229–243 (2015). 
59. Haughney, S. L. et al. Retention of structure, antigenicity, and biological function 
of pneumococcal surface protein A (PspA) released from polyanhydride 





CHAPTER 4.    COMBINATION NANOVACCINE PROVIDES PROTECTION 
AGAINST YERSINIA PESTIS IN MICE WITH IMMUNOLOGICAL 
DEFICIENCIES 
Danielle A Wagner-Muñiz1, Sean M Kelly2, Andrew C Petersen1, Nathan Peroutka-
Bigus1,3, Ross J Darling1, Bryan H Bellaire1,3,4, Michael J Wannemuehler1,4, and Balaji 
Narasimhan2,4 
 
1Department of Veterinary Microbiology and Preventive Medicine, Iowa State 
University, Ames, IA, USA 2Department of Chemical and Biological Engineering, Iowa 
State University, Ames, IA, USA 3Interdepartmental Microbiology, Iowa State 




Use of inbred mice as a biological model in scientific research is common across 
many different fields of biomedical research. Differences have been described between 
differentially sourced mice, and though they are rare, can have a significant impact on  
biological discoveries1,2. Though uncommon, it is possible for spontaneous genetic 
mutations to arise in certain mouse colonies, particularly those using the practice of 
backcrossing3. One such mutation, first described in 2016, entails a double variant 
mutation in the 28 and 29 exons of the gene Dock24.  
Dock2, dedicator of cytokinesis 2, is a member of the Caenorhabditis elegans 
Ced-5, mammalian DOCK180 and Drosophila melanogaster myoblast city (CDM) 
family of scaffolding proteins, that is highly expressed in leukocytes and is known to play 
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a key role in chemokine-related lymphocyte migration5–7. Other members of the CDM 
protein family, such as Dock180, have been shown to play a key role in the activation of 
the GTPase Rac, a regulator of the actin cytoskeleton8,9.   
Loss of Dock2 functionality, in Dock2-/- mouse models, has been associated with 
decreased chemokine responsiveness, B and T cell migratory defects, loss of marginal 
zone B cell populations and malformities in the lymph node follicles, and impaired 
polarity/chemotaxis of plasmacytoid dendritic cells (pDCs).5,10 The absence of Dock2, 
however does not seem to effect neutrophil trafficking or monocyte activation in regards 
to chemokines5,11,12. Fukui et al. also described abnormal thymus architecture and 
reduced B and T cell homing to the spleen in mice lacking Dock2.  
Though lymphocyte migration is significantly hindered in Dock2-/- mice, it is not 
entirely absent, operating at approximately 10% of normal capacity13. The small subset of 
Dock2-/- lymphocytes that are capable of migrating, may be doing so in a PI3K-
dependent manner5,14–16. Loss of Dock2 also results in lowered populations of CD4 T 
cells in the periphery and secondary lymphoid tissues, as well as the inability to maintain 
CD4 T cells numbers following transfer, indicating Dock2 may also play role in cell 
survival13. Dock2-/- T cells express normal levels of integrins following activation and 
adhere to high endothelial venules inside secondary lymphoid organ (SLO), but fail to 
properly extravasate into lymphoid tissue despite the capability of normal 
transendothelial migration in the absence of Dock214,17 
Unlike T cells, B cells show no integrin activation in the absence of Dock2 and do 
not adhere in SLO venules indicating a differential role for Dock2 in T and B cell 
chemokine-mediated migration.  Total B cell precursor population numbers are largely 
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unchanged in the absence of Dock2, rather they experience a marked decrease in 
chemotactic responsiveness16. Reduced motility in the follicles and paracortex of lymph 
nodes has been observed in Dock2-/- mice and was coupled with a reduced egress of 
activated B and T cells from the peripheral lymph nodes15. Additionally, it was found that 
CD8+ T cells, from Dock2-/- mice, express significantly lower levels of IFN-γ, granzyme 
B, and perforin, due to decreased numbers of lymphocytes in lymphoid tissue18. Though 
uncommon, Dock2 mutations have been documented in a small subset of the human 
population, with clinical manifestations of early-onset invasive infections in children19.  
Following correspondence with Envigo, about the source and genotype of the 
mice used for these studies, it was confirmed that they were from barriers/breeding 
facilities (locations 206, 208, or 231) where C57BL/6NHsd mice containing the Dock2 
double variant mutation were present (Appendix). While the genotype of the mice in 
these studies has not yet been confirmed, we hypothesize that they did in fact contain a 
mutation. This conclusion is based on the observation that these mice presented with a 
reduced humoral response that is characteristic of mice with the Dock2 mutation as 
previously described4,20. The data herein describes the induction of a protective immune 
response in mice sourced from Envigo (C57BL/6NHsdENV) following immunization with 
a Combination Nanovaccine formulation, comprised of F1-V-encapsulated into 
polyanhydride nanoparticles and co-adjuvanted with cyclic dinucleotide cdG (CDNs).  
Materials and Methods 
Materials 
Chemicals used for CPTEG and CPH diacid and polymer synthesis included 1,6-
dibromohexane, triethylene 4-p-hydroxybenzoic acid, and 1-methyl-2-pyrrolidinone, 
purchased from Sigma-Aldrich (St. Louis, MO). Chloroform, petroleum ether, ethyl 
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ether, hexanes, sodium hydroxide, toluene, sulfuric acid, acetonitrile, dimethyl 
formamide, acetic anhydride, methylene chloride, pentane, and potassium carbonate were 
purchased from Fisher Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile was purchased 
from Apollo Scientific (Cheshire, UK). Deuterated chloroform used for 1H NMR analysis 
was purchased from Cambridge Isotope Laboratories (Andover, MA). Dithio-RP,RP-
cyclic di-guanosine monophosphate (R,R-Cyclic di-GMP (cdG)) was provided by Aduro 
Biotech (Berkeley, CA). Complete cell culture medium reagents RPMI 1640 and 
penicillin-streptomycin were purchased from Mediatech (Herndon, VA); heat inactivated 
fetal calf serum was purchased from Atlanta Biologicals (Atlanta, GA). Y. pestis, strain 
CO92 (NR-641) and the Y. pestis fusion protein F1-V (NR-4526) were obtained from the 
Biodefense and Emerging Infections Repository (Manassas, VA). 
Polyanhydride synthesis 
CPTEG and CPH diacids were synthesized as previously described 21,22. 20:80 
CPTEG:CPH copolymer synthesis was performed using melt polycondensation 21. 
Copolymer composition and molecular weight were estimated using end group analysis 
of 1H NMR (DXR 500) spectra.  
Nanoparticle synthesis 
10 % (w/w) F1-V-loaded 20:80 CPTEG:CPH nanoparticles were synthesized 
using flash nanoprecipitation, as described previously 23. Briefly, F1-V and 20:80 
CPTEG:CPH copolymer was dissolved in methylene chloride at 2 mg/mL and 20 
mg/mL, respectively, sonicated at 30 Hz for approximately 30 seconds, and poured into 
pentane chilled to -20 °C at a methylene chloride:pentane ratio of 1:250. Nanoparticles 
were imaged using scanning electron microscopy (SEM; JEOL 840 A, JEOL Ltd., 
Tokyo, Japan), and nanoparticle mean size and size distribution were determined using 
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ImageJ (National Institutes of Health, Bethesda, MD). Nanoparticle zeta potential was 
measured using Zetasizer Nano (Malvern Instruments, Worcestershire, UK).  
Animals 
Seven to eight-week old female mice were purchased, C57BL/6NHsd from 
Envigo (Somerset, NJ) or C57Bl/6NCrlWT from Charles River (Wilmington, MA). Mice 
were housed under specific pathogen-free conditions where all bedding, caging, water, 
and feed were sterilized prior to use. All studies were conducted with the approval of the 
Iowa State University Institutional Animal Care and Use Committee (IACUC). 
Immunization and serum collection 
Groups comprised of C57BL/6 mice (n = 8-16/group) were immunized 
subcutaneously at the nape of the neck with either of the following: 50 µg F1-V + 35 µg 
CDNs (R,R-CDG, Aduro Biotech), 50 µg F1-V encapsulated into 500 µg of 20:80 
CPTEG:CPH nanoparticles, 50 µg F1-V encapsulated into 500 µg of 20:80 CPTEG:CPH 
nanoparticles + 35 µg CDNs, or saline in a total volume of 200 µL. Blood was collected 
via saphenous vein and serum was separated following centrifugation (10,000 rcf for 10 
min) at 12, 13, 42, 70, 100, and 114 DPI. Serum was stored at -20°C until analysis.  
ELISA 
Anti-F1-V antibody titers were determined via ELISA, as previously described 24. 
Briefly, high-binding Costar 590 EIA/RIA microtiter plates (Corning) were coated 
overnight with 100 µL of a 0.5 µg/mL solution of F1-V at 4 °C. After washing the wells, 
microtiter plates were blocked for two hours with a solution of 2.5% (w/v) powdered 
skim milk dissolved in PBS-Tween with 0.05% Tween 20, pH 7.4, that had been 
incubated for two hours at 56 °C to inactivate any endogenous phosphatase activity. 
Microtiter plates were washed thrice with PBS-T. Serum obtained from immunized mice 
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was added at a dilution of 1:200 and serially diluted in PBS-T containing 1% (v/v) goat 
serum. Samples were tested in duplicate. Following incubation overnight at 4°C, plates 
were washed thrice with PBS-T, after which secondary antibody was added at a dilution 
of 1 µg/mL. Secondary antibodies used in these studies were: alkaline phosphatase-
conjugated goat anti-mouse IgG heavy and light chain (Jackson ImmunoResearch). Plates 
were incubated for two hours at room temperature and washed three times with PBS-T. 
To each well, 100 µL of alkaline phosphatase substrate (Fisher Scientific, Pittsburgh, PA) 
was added at a concentration of 1 mg/mL dissolved in 50 mM sodium carbonate, 2 mM 
magnesium chloride buffer at pH 9.3 for colorimetric development. Plates were analyzed 
after 30 min using a SpectraMax M3 microplate reader at a wavelength of 405 nm. Titer 
is reported as the reciprocal of serum dilution at which the optical density (OD) value 
was at most 0.2.  
Challenge 
Y. pestis CO92 (NR-641) was obtained from BEI Resources. Frozen stocks were 
prepared in advance of challenges. Y. pestis was initially grown on brain heart infusion 
(BHI) agar at 28 °C for 72 h; a single colony was isolated and inoculated in BHI broth 
and cultivated for 24 h at 28 °C while shaking at 120 rpm. Glycerol solution was added to 
the broth to bring final glycerol concentration to 5% (v/v). Aliquots were snap frozen and 
stored at -72 °C. Prior to challenge experiments, aliquots of the frozen stock were thawed 
and cultured on tryptic soy agar (TSA) with 1% bovine hemoglobin at 37°C and 5% CO2 
to check viability and CFU enumeration. For challenge experiments, frozen Y. pestis 
stocks were thawed and diluted in room temperature PBS. Groups of C57BL/6 mice were 
anesthetized with an intraperitoneal injection of ketamine/xylazine cocktail and infected 
intranasally with 8,000-8,500 CFU (14 and 120 DPI) of Y. pestis CO92 in 50 µL volume. 
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Y. pestis bacterial suspension was administered intranasally to nares of mice by a 
micropipette. CFU enumeration was performed on infectious inoculum preceding to and 
following infection of the animals to determine infectious dose administered. Animals 
were checked daily for morbidity and mortality over the course of 12-14 days post-
challenge. All activities were performed in an animal biosafety level 3 (ABSL-3) 
laboratory at Iowa State University with protocols approved by the IACUC and 
Institutional Biosafety Committee (IBC).  
Statistical analyses 
Statistical analyses on the ELISA data as well as the survival data were performed 
using the Mantel-Cox log rank test and the one-way analysis of variance (ANOVA) using 
Tukey’s multiple comparisons test. A p-value ≤ 0.05 was considered to be statistically 
significant. All analyses were performed using GraphPad Prism v. 7.0 (GraphPad, La 
Jolla, CA). 
Results 
Combination Nanovaccine Provides Early-Onset Protection 
In order to assess rapidly-induced protection, separate groups of 
C57BL/6NHsdENV mice were immunized subcutaneously as described in Table 4.1. 
Serum was collected from vaccinated mice at 12 days post-immunization (DPI) and 
analyzed via ELISA for anti-F1-V specific IgG (H+L) to charaterize the humoral immune 
response. Mice were challenged intranasally at 13 DPI with 8500 CFUs of Y. pestis strain 
CO92. Mice immunized with Combination Nanovaccine formulation showed signifcantly 
(p < .05) higher anti-F1-V-specific titers compared to that induced by the Nanovaccine 
alone (Figure 4.1A). Following challenge, immunization with the Combination 
Nanovaccine induced 100 % survival which was signifcantly (p ≤ .025) better protection 
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than that indiced by any other vaccine regimen (Figure 4.1B). CDN Vaccine provided for 
50% protection, but did not provide superior protection compared to other vaccinated 
groups. Nanovaccine alone provided 25% protection, while 12.5 % of the soluble F1-V 
protein alone and the saline treated mice survived the Y. pestis CO92 challenge.  
Table 4.1Vaccine formulations. Vaccine formulations were comprised of soluble F1-V 
protein, F1-V encapsulated into 20:80 CPTEG:CPH nanoparticles at 10% w/w loaded, 
and soluble CDNs (cdG). 
 
 
Long-Term Protection Observed in Adjuvanted Vaccine Formulations  
 To determine whether long-term protection was induced, C57BL/6NHsdENV mice 
were immunized subcutaneously as described in Table 4.1. Serum was collected at 12, 
42, 70, 100, and 114 DPI and analyzed via ELISA for antigen-specific IgG (H+L) (Figure 
4.2A). Regardless of the time point, Combination Nanovaccine-immunized mice showed 
significantly (p ≤ .04) increased titers compared to serum from mice immunized with 
soluble F1-V, and significantly (p ≤ .008) higher titers than Nanovaccine at 14 and 42 







Figure 4.1 Efficacy of various F1-V containing vaccine regimen against lethal Y. pestis CO92 challenge.  Serum from 
subcutaneously immunized mice (n = 8-16) was collected at 12 DPI and analyzed for total anti-F1-V-specific IgG (A). 
Animals were challenged intranasally with 8500 CFUs of Y. pestis at 14 DPI and survival was assessed for 14 days post-
challenge (B). * indicates significant difference (p ≤ .05) as compared to F1-V group. # indicates significant difference (p ≤ 
.029) as compared to all formulation groups.
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Mice immunized with CDN Vaccine showed significantly (p ≤ .04) higher titers 
than those immunized with F1-V alone at 42, 70, and 101 DPI, and significantly (p ≤ .02) 
higher titers than Nanovaccine at 42 DPI.   
A challenge dose of 8000 CFUs of Y. pestis CO92 was administered intranasally 
at 120 DPI. All adjuvanted formulations (Combination Nanovaccine, Nanovaccine, and 
CDN Vaccine) performed similarly providing 71-75% protection from lethal challenge, 
that was significantly (p ≤ .05) higher than the 12.5 to 15 % protection for the mice 
vaccinated with soluble F1-V alone or saline (Figure 4.2B). IgG class switching was 
evaluated for F1-V-specific IgG1 and IgG2c at all time points (Figure 4.2C). IgG1 was 
measurable in all vaccinated groups, with CDN Vaccine showing significantly (p ≤ .02) 
higher IgG1 titers than F1-V alone at all time points, and in mice receiving the 
Nanovaccine at 14 and 79 DPI. IgG1 responses were also significantly (p ≤ .05) higher in 
Combination Nanovaccine as compared to F1-V, at 14 and 79 DPI, and Nanovaccine at 
14 DPI. F1-V-specific IgG2c was only observed in vaccine formulations adjuvanted with 
CDNs (CDN Vaccine and Combination Nanovaccine), and was significantly (p ≤ .01) 
higher than F1-V or Nanovaccine at all time points indicating that addition of CDNs 







Figure 4.2 Long-Term Protection Observed in Adjuvanted Vaccine Formulations. Serum 
from subcutaneously immunized mice (n=7-16) at 14, 42, 79, 101, and 114 DPI was 
analyzed for total anti-F1-V-specific IgG (A). Dashed line indicates titer of Saline control 
mice. Animals were challenged intranasally at 120 DPI and survival was assessed for 12 
days post-challenge (B). IgG class switching was characterized at all time points and is 
reported as an OD value at a dilution of 1:500 (C/D). * indicates significant difference (p 
≤ .04) as compared to F1-V group. # indicates significant difference (p ≤ .015) as 




Varying Humoral Immune Response Observed Between Differentially-Sourced 
Mice 
Vaccination of both Envigo-sourced mice (C57BL/6NHsdENV) and Dock2 
wildtype mice sourced from Charles River (C57Bl/6NCrlWT) showed varying levels of 
humoral immunity. Mice were immunized subcutaneously with vaccine formulations 
described in Table 4.1. Total serum anti-F1-V IgG was assessed via ELISA at 14, 49, and 
70 DPI. Titers observed in C57Bl/6NCrlWT mice were significantly (p ≤ .05) higher (i.e, 
four to 10-fold increase) than those measured in C57BL/6NHsdENV mice when CDNs 
were included in the vaccine regimen (Combination Nanovaccine and CDN Vaccine) 
across all time points (Figure 4.3A). Comparison of the kinetics of the humoral response 
between C57BL/6NHsdENV and C57Bl/6NCrlWT mice immunized with the Combination 
Nanovaccine showed peak antibody titers in C57Bl/6NENV mice at 14 DPI, while 
immunized C57Bl/6NCrlWT presented with increasing antibody titers up to at least 101 
DPI (Figure 4.3B). Comparison of the IgG2c:IgG1 ratio between C57BL/6NHsdENV and 
C57Bl/6NCrlWT demonstrated a higher IgG2c:IgG1 ratio in Combination Nanovaccine-
immunized mice as compared to all other vaccinated groups in the Envigo-sourced mice, 






Figure 4.3 Varying Humoral Immune Response Observed Between Differentially-
Sourced Mice. Serum from subcutaneously immunized C57BL/6NHsdENV and 
C57BL/6NCrlWT mice (n=7-16) at 14, 42, and 79 DPI was analyzed for total anti-F1-V-
specific IgG (A). Comparison of the kinetics of the humoral immune response following 
immunization with Combination Nanovaccine, as measured by total serum IgG for 
C57BL/6NHsdENV compared to C57BL/6NCrlWT (B). IgG2c:IgG1 in immunized 





Cell motility plays a critical role in the overall function of the immune system, 
contributing to cell trafficking, activation, proliferation, and the architecture of secondary 
lymphoid structures. While the actin cytoskeleton is primarily responsible for proper 
immune synapse formulation and the ability of cells to extravasate from the circulation to 
their appropriate locations, other factors such as chemokines, cell surface 
receptors/ligands, adhesion molecules, and the downstream signaling resulting from these 
interactions also play an equally important role. One such key player in cell motility is 
Dock2.  
In addition to reduced overall cell motility in the secondary lymphoid tissues, 
activation, and cell trafficking between tissues, mice with a double variant of the Dock2 
gene have been found to be lacking marginal zone B cells4.  Though the absence of this 
cell population primarily influences the spleen, in terms of secondary lymphoid organs, it 
is possible that this deficit in the B cell population could play some role in the decreased 
overall humoral immune response in these Dock2-/- mice. Removal of an entire subset of 
B cells could also alter the overall functionality of other cell types, due to altered 
secondary tissue architecture or the decrease of certain cytokine/chemokine levels. 
Because Dock2’s function in regulation of actin cytoskeleton rearrangement, it is possible 
that it plays a critical role in other functions not related to chemokine-mediated 
migration, such as immune synapse formation, initiation of signaling cascades, and 
apoptosis.  
The data herein demonstrates that immunization of C57BL/6NHsdENV mice with 
Combination Nanovaccine formulation was able to induce both rapid and long-lived 
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protection (at 14 and 120 DPI, respectively) against lethal Y. pestis CO92 challenge 
(Figures 4.1 and 4.2), despite lower overall titers as compared to WT mice. Combination 
Nanovaccine immunization conferred 100% protection against lethal challenge at 14 DPI 
(Figure 4.1B). Additionally, all adjuvanted vaccine formulations (i.e. Combination 
Nanovaccine, Nanovaccine, CDN Vaccine) were capable of conferring 71-75% 
protective immunity at 120 DPI (Figure 4.2B).  
Class-switching to IgG2c was observed in both CDN Vaccine and Combination 
Nanovaccine formulations, though Combination Nanovaccine showed higher ratios of 
IgG2c:IgG1 (Figure 4.3). While loss of Dock2 functionality has been associated with 
decreased germinal center responses, it has been suggested that class-switching is 
determined between 7-10 days post-infection/-immunization and occurs prior to germinal 
center formation4,25,26. Therefore, it is possible the class-switching observed here is 
occurring in the absence of germinal center formation.   
While the genotype of these C57BL/6NHsdENV mice cannot be confirmed, 
comparison of the humoral immune response following vaccination to WT mice shows a 
strikingly different immune phenotype. F1-V-specific IgG titers observed in WT 
vaccinated mice were 4-10 times higher and showed peak antibody titers at a later time 
point (101 DPI) as compared to those measured in serum from C57BL/6NHsdENV (Figure 
4.3). Analysis of the kinetics of the humoral immune response in C57BL/6NHsdENV mice 
may seem to indicate a predominantly short-lived plasma cell or extrafollicular antibody 




While Dock2-/- mice were shown to have severely atrophied T and B cell areas of 
the lymph nodes, they do form rudimentary white pulp cords that serve to maintain a 
modicum of lymphocyte populations17. It is hypothesized that this small subset of 
normally functioning immune cells, may migrate using a PI3K-dependent mechanism 
which would represent biological redundancy associated with cell motility. This may help 
to explain why a measurable humoral immune response following vaccination, though at 
a significantly lower level than that measured in WT mice receiving the same vaccine 
formulation. 
Though impaired  cell trafficking makes it unlikely that long-lived plasma cells 
(LLPCs) induced by these vaccine formulations would be able to migrate to the bone 
marrow, it has been previously demonstrated that LLPCs do maintain small populations 
in the spleen and lymph nodes for up to 10 years following primary immunization27. It is 
possible that the long-lived protective immune response observed here could be due to 
long-lived antibody secreting cells present in the secondary lymphoid tissues. 
Additionally, it has been described by Darling et al., that CDNs induce BAFF expression, 
which may contribute to the development and survival of LLPCs in the secondary 
lymphoid tissue.  
In addition to impaired B cell development, Mahajan et al. also described the 
presence of an unusually large proportion of memory CD8+ T cells circulating in the 
periphery of double variant Dock2 mice. It is possible that this population of T cells could 
also be contributing to overall protection from Y. pestis infection through the production 
of IFNγ and activation of macrophages, which has been linked to protection against 
pneumonic plague28.  
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Though Dock2 mutations are uncommon, there are many other immunological 
deficiencies in the general population, which are associated with decreased overall 
humoral immune responses. One such population exhibiting decreased humoral responses 
are HIV infected individuals, which show significantly decreased antibody production in 
comparison to healthy individuals largely due to decreased CD4+ T cell populations29,30. 
Actin cytoskeleton-associated immunodeficiencies, such as Wiskott-Aldrich Syndrome, 
mutations in Dock8 gene, autosomal-recessive hyper IgE syndrome (AR-HIES), and 
Epidermodysplasia verruciformis, all exhibit decreased humoral immune responses as 
well31.  In these instances, use of a vaccine that is capable of inducing strong humoral 
immune responses, such as those observed following Combination Nanovaccine 
immunization in both C57BL/6NHsdENV and WT mice, could be able to increase overall 
vaccine efficacy in immunodeficient individuals.  
The development of next-generation vaccines, which can overcome 
immunological defects such as Dock2, is critically important when considering the 
vaccination of a biologically diverse population. While many vaccines do offer sufficient 
protection in healthy individuals, use of a vaccine that is better able to induce protective 
immune responses in immunodeficient individuals provides an opportunity for higher 
overall levels of protective immunity. The use of co-adjuvants, such as CDNs and 
polyanhydride nanoparticles, allows for a synergistic approach towards vaccine 
development which may be able to overcome such immune defects in the general 
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Introduction 
 Successful control of Yersinia pestis (Y. pestis) infection is contingent upon 
activation of both innate and adaptive branches of the immune system. Following 
primary infection, the innate immune system is of extreme importance in controlling 
early bacterial replication. The majority of Y. pestis bacterium entering the host are 
immediately killed by neutrophils; however, many evade the immune system by 
preferentially infecting host macrophages. The adaptive humoral immune response 
contributes to the control of extracellular bacteria by neutralizing Y. pestis virulence 
factors (e.g., V antigen) and inhibiting infection of macrophages.  Additionally, the 
cellular immune response and production of pro-inflammatory cytokines such as 
interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα) can contribute to 
control of bacterial replication and overall protective immune response, particularly in 
pulmonary infections1,2.  
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Engulfment of micro-organisms by Ly-6G+ neutrophils is capable of controlling 
Y. pestis growth and spread of infection in the first 48 hours post-infection3. At 72-96 
hours post-infection, the bacterium is primarily found inside CD11b+ macrophages, 
which allows the pathogen to evade host immunity, as well as traffic to secondary 
lymphoid tissues4. It is there, inside host macrophages, Y. pestis begins to replicate and 
upregulate expression of the type III secretion system, and downregulates the 
macrophage-induced pro-inflammatory response5.  Upon escape from the macrophage, Y. 
pestis can further evade the immune response by insertion of Yersinia effector proteins 
(Yops) into the cytosol of target host cells6. It has been previously described that pre-
treatment of macrophages in vitro with IFNγ and TNFα can help to overcome these 
mechanisms of immunosuppression3.  
 In order for a vaccine to overcome the Y pestis mechanisms of immune evasion, it 
is important to engage both the innate and adaptive immune response. Though the innate 
immune response is relatively short, in comparison to adaptive immunity, it is possible 
for it to have a large impact on overall infection outcome over a prolonged period of 
weeks to months through the process of trained innate immunity7,8.  
Trained immunity is induced following a primary infection or vaccination through 
epigenetic reprogramming of monocytes, macrophages, and natural killer (NK) cells, 
which directly alter cellular metabolism and activation of immune signaling pathways9,10. 
Metabolically, trained monocytes exhibit a shift from oxidative phosphorylation to 
glycolysis, and have epigenetic changes present in genes involved in the mammalian 
target of rapamycin (mTOR) pathway11.  
The trained immune response primarily involves activation of neutrophils and 
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monocyte-derived macrophages, and has been shown to confer cross-protection against 
nonrelated secondary infections at 7 days following initial infection, in a T and B cell 
independent manner12,13. It has been observed that trained monocytes show increased 
histone methylation, as well as, increased transcription of genes encoding IL-6 and TNFα 
following secondary heterologous challenge12. Trained monocytes and macrophages 
stimulated ex vivo following infection, were shown to have larger capacity for IL-6 and 
TNFα production, as compared to naïve cells for two weeks post-challenge, and had 
increased reactive oxygen species production for three weeks following infection14.  
Though the mechanisms surrounding the development of trained innate immunity 
are still being fully elucidated, several transcription factors have been identified that may 
play a large impact on epigenetic and transcriptional programming. Of particular interest, 
it has been reported that inhibiting synthesis of cyclic adenosine monophosphate (cAMP) 
or mTOR during the primary response eliminates the protective effect of trained innate 
immunity following secondary infection in human and murine models11,15.  
By incorporating adjuvants, that are capable of activating the innate immune 
responses and that induce trained immunity, into vaccine formulations, we may be better 
able to rationally design vaccines capable of providing rapid protection, prior to full 
activation of the humoral immune response, necessary in outbreak scenarios. Herein, the 
capacity of Combination Nanovaccine and CDN Vaccine formulations, previously 
described in Chapters 3 and 4, to induce protective immunity at both 5 and 10 days post-
immunization (DPI) was evaluated. Additionally, the impact of the pro-inflammatory 
cytokines IFNγ and TNFα on vaccine-induced protective immunity against lethal 
pulmonary Y. pestis infection was evaluated at 14 DPI.  
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Materials and Methods 
Materials 
Chemicals used for CPTEG and CPH diacid and polymer synthesis included 1,6-
dibromohexane, triethylene 4-p-hydroxybenzoic acid, and 1-methyl-2-pyrrolidinone, 
purchased from Sigma-Aldrich (St. Louis, MO). Chloroform, petroleum ether, ethyl 
ether, hexanes, sodium hydroxide, toluene, sulfuric acid, acetonitrile, dimethyl 
formamide, acetic anhydride, methylene chloride, pentane, and potassium carbonate were 
purchased from Fisher Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile was purchased 
from Apollo Scientific (Cheshire, UK). Deuterated chloroform used for 1H NMR analysis 
was purchased from Cambridge Isotope Laboratories (Andover, MA). Dithio-RP,RP-
cyclic di-guanosine monophosphate (R,R-Cyclic di-GMP (cdG)) was provided by Aduro 
Biotech (Berkeley, CA). Complete cell culture medium reagents RPMI 1640 and 
penicillin-streptomycin were purchased from Mediatech (Herndon, VA); heat inactivated 
fetal calf serum was purchased from Atlanta Biologicals (Atlanta, GA). Y. pestis, strain 
CO92 (NR-641) and the Y. pestis fusion protein F1-V (NR-4526) were obtained from the 
Biodefense and Emerging Infections Repository (Manassas, VA). 
Polyanhydride synthesis 
CPTEG and CPH diacids were synthesized as previously described 16,17. 20:80 
CPTEG:CPH copolymer synthesis was performed using melt polycondensation 16. 
Copolymer composition and molecular weight were estimated using end group analysis 
of 1H NMR (DXR 500) spectra.  
Nanoparticle synthesis 
10 % (w/w) F1-V-loaded 20:80 CPTEG:CPH nanoparticles were synthesized 
using flash nanoprecipitation, as described previously 18. Briefly, F1-V and 20:80 
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CPTEG:CPH copolymer was dissolved in methylene chloride at 2 mg/mL and 20 
mg/mL, respectively, sonicated at 30 Hz for approximately 30 seconds, and poured into 
pentane chilled to -20 °C at a methylene chloride:pentane ratio of 1:250. Nanoparticles 
were imaged using scanning electron microscopy (SEM; JEOL 840 A, JEOL Ltd., 
Tokyo, Japan), and nanoparticle mean size and size distribution were determined using 
ImageJ (National Institutes of Health, Bethesda, MD). Nanoparticle zeta potential was 
measured using Zetasizer Nano (Malvern Instruments, Worcestershire, UK).  
Animals 
Seven to eight-week old female C57BL/6NCrl mice were purchased from Charles 
River (Wilmington, MA). Mice were housed under specific pathogen-free conditions 
where all bedding, caging, water, and feed were sterilized prior to use. All studies were 
conducted with the approval of the Iowa State University Institutional Animal Care and 
Use Committee (IACUC). 
Immunization and serum collection 
Groups comprised of C57BL/6Crl mice (n = 8-16/group) were immunized 
subcutaneously (sc) at the nape of the neck with either of the following: 50 µg F1-V + 35 
µg CDNs (R,R-CDG, Aduro Biotech), 50 µg F1-V encapsulated into 500 µg of 20:80 
CPTEG:CPH nanoparticles + 35 µg CDNs, or saline in a total volume of 200 µL. Blood 
was collected via saphenous vein and serum was separated following centrifugation 
(10,000 rcf for 10 min) at 4, 9, and 13 DPI. Serum was stored at -20°C until analysis.  
ELISA 
Anti-F1-V antibody titers were determined via ELISA, as previously described 19. 
Briefly, high-binding Costar 590 EIA/RIA microtiter plates (Corning) were coated 
overnight with 100 µL of a 0.5 µg/mL solution of F1-V at 4 °C. After washing the wells, 
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microtiter plates were blocked for two hours with a solution of 2.5% (w/v) powdered 
skim milk dissolved in PBS-Tween with 0.05% Tween 20, pH 7.4, that had been 
incubated for two hours at 56 °C to inactivate any endogenous phosphatase activity. 
Microtiter plates were washed thrice with PBS-T. Serum obtained from immunized mice 
was added at a dilution of 1:200 and serially diluted in PBS-T containing 1% (v/v) goat 
serum. Samples were tested in duplicate. Following incubation overnight at 4°C, plates 
were washed thrice with PBS-T, after which secondary antibody was added at a dilution 
of 1 µg/mL. Secondary antibodies used in these studies were: alkaline phosphatase-
conjugated goat anti-mouse IgG heavy and light chain (Jackson ImmunoResearch). Plates 
were incubated for two hours at room temperature and washed three times with PBS-T. 
To each well, 100 µL of alkaline phosphatase substrate (Fisher Scientific, Pittsburgh, PA) 
was added at a concentration of 1 mg/mL dissolved in 50 mM sodium carbonate, 2 mM 
magnesium chloride buffer at pH 9.3 for colorimetric development. Plates were analyzed 
after 30 min using a SpectraMax M3 microplate reader at a wavelength of 405 nm. Titer 
is reported as the reciprocal of serum dilution at which the optical density (OD) value 
was at most 0.2.  
Challenge 
Y. pestis CO92 (NR-641) was obtained from BEI Resources. Frozen stocks were 
prepared in advance of challenges. Y. pestis was initially grown on brain heart infusion 
(BHI) agar at 28 °C for 72 h; a single colony was isolated and inoculated in BHI broth 
and cultivated for 24 h at 28 °C while shaking at 120 rpm. Glycerol solution was added to 
the broth to bring final glycerol concentration to 5% (v/v). Aliquots were snap frozen and 
stored at -72 °C. Prior to challenge experiments, aliquots of the frozen stock were thawed 
and cultured on tryptic soy agar (TSA) with 1% bovine hemoglobin at 37°C and 5% CO2 
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to check viability and CFU enumeration. For challenge experiments, frozen Y. pestis 
stocks were thawed and diluted in room temperature PBS. Groups of C57BL/6Crl mice 
were anesthetized with an intraperitoneal injection of ketamine/xylazine cocktail and 
infected intranasally with 7,000 to 10,000 CFU of Y. pestis CO92 in 50 µL volume at 4, 
9, or 14 DPI. Y. pestis bacterial suspension was administered intranasally to nares of mice 
by a micropipette. CFU enumeration was performed on infectious inoculum preceding to 
and following infection of the animals to determine infectious dose administered. 
Animals were checked daily for morbidity and mortality over the course of two weeks. 
All activities using Y. pestis were performed in a biosafety level 3 (ABSL-3) laboratory at 
Iowa State University with protocols approved by the IACUC and Institutional Biosafety 
Committee (IBC).  
Statistical Analyses 
Statistical analyses on the ELISA data as well as the survival data were performed 
using the Mantel-Cox log rank test and the one-way analysis of variance (ANOVA) using 
Tukey’s multiple comparisons test. A p-value ≤ 0.05 was considered to be statistically 
significant. All analyses were performed using GraphPad Prism v. 7.0 (GraphPad, La 
Jolla, CA). 
IFNγ and TNFα Cytokine Neutralization 
Mice received 1 mg each anti-TNFα (rat IgG1, XT3.11) mAb and anti-IFNγ (rat 
IgG1, XMG1.2) mAb delivered intraperitoneally in 500 µL PBS one day before 
challenge.  
Serum Cytokine Analysis 
 Serum was collected at 4, 9, or 13 DPI, diluted 1:4, and analyzed for 
presence of IL-1β, IL-4, IL-6, TNF-α, IL-12p40, and IFN-γ using multiplex cytokine 
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assay as previously described20 and analyzed via Bio-Plex 200™ system (Bio-Rad, 
Hercules, CA).  
Results 
Protection against lethal Y. pestis challenge at 5 and 10 days post-immunization  
 In order to assess the humoral and protective immune response at very early time 
points post-immunization (5 and 10 days), two independent experiments were conducted. 
Mice were immunized sc with one of the formulations outlined in Table 5.1. Serum was 
collected at 4 or 9 days post-immunization (DPI) and analyzed for total IgG via ELISA 
(Figure 5.1 A and C). There was no detectable anti-F1-V specific IgG (H+L) at 4 DPI 
(Figure 5.1 A); however, by 9 DPI, there was a significant (p ≤ .05) increase in titer for 
each vaccine group, with the CDN Vaccine and the Combination Nanovaccine inducing 
similar titers (Figure 5.1 A and C). In the first set of experiments shown in Figure 5.1 
panels A and B, mice were challenged intranasally at 5 or 10 DPI with 10,000 CFUs of 
Yersinia pestis strain CO92. Vaccination with the Combination Nanovaccine provided 
100 % protection at 10 DPI, performing significantly (p ≤ .01) better than all other 
vaccine formulas where all mice in these treatment groups succumbed to infection by 
four days post-challenge (Figure 5.1B).  For the second experimental iteration, as shown 
in Figure 5.1 panels C and D, mice were challenged at 10 DPI with 7,000 CFUs of Y. 
pestis strain CO92. CDN Vaccine-immunized mice showed significantly (p ≤ .03) 
increased survival (i.e., 87.5 %) while only 37 % % of the mice treated with the 
Combination Nanovaccine survived (Figure 5.1 D). 
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Table 5.1 F1-V vaccine formulations. Formulations used in this study were comprised of 
soluble F1-V protein, F1-V encapsulated into 20:80 CPTEG:CPH nanoparticles at 10% 




Neutralization of IFNγ/TNFα impacts challenge outcome 
 In order to analyze the importance of pro-inflammatory cytokines IFNγ 
and TNFα on protection at 14 DPI, mice were immunized with Combination 
Nanovaccine formulation outlined in Table 5.1. Anti-F1-V specific serum IgG was 
analyzed at 13 DPI via ELISA and was found to be similar across all immunized mice 
(Figure 5.2 A). Cytokines (IFNγ and TNFα ) were neutralized one day prior to challenge 
using specific mAbs delivered intraperitoneally. Mice were challenged intranasally with 
7000 CFUs of Y. pestis CO92 at 14 DPI and survival was monitored for 14 days post-
challenge. Mice, in which IFNγ and TNFα were neutralized showed significantly (p ≤ 
.03) less survival than Combination Nanovaccine-immunized mice that did not have 
cytokines neutralized prior to challenge (Figure 5.2 B). Combination Nanovaccine and 









Figure 5.1 Protection against lethal Y. pestis challenge at 5 and 10 DPI. Serum from immunized mice (n = 6-16) was collected at 4 (A) 
or 9 (A/C) DPI and analyzed for total anti-F1-V-specific IgG DPI. Mice were challenged intranasally with 10000 (B) or 7000 (D) 





Figure 5.2 Neutralization of IFNγ and TNFα decreases overall survival. Mice were 
immunized subcutaneous with Combination Nanovaccine formulation. Total F1-V 
specific serum IgG was determined at 13 DPI via ELISA (A). Animals (n = 4-16) were 
challenged intranasally at 14 DPI with 7000 CFU of Y. pestis and survival was assessed 




Serum cytokine analysis  
 To evaluate potential cytokines that may impacting protection at early timepoints, 
serum was collected from mice immunized as part of the experiments outlined in Figure 
5.1 A-D, at 4, 9, or 13 DPI. Serum was analyzed for presence of IL-1β, IL-4, IL-6, TNF-
α, IL-12p40, and IFN-γ using multiplex cytokine assay. The only detectable cytokine in 
the serum of immunized mice regardless of the time point and treatment group was IL-
12p40 (Figure 5.3). No significant differences were observed between groups.  
 
Figure 5.3 Analysis of serum cytokine expression. Mice were immunized subcutaneously 
and serum was evaluated at 4, 9, or 13 DPI for presence of IL-1β, IL-4, IL-6, TNF-α, 
IFN-γ (data not shown) and IL-12p40 using multiplex cytokine assay.  
 
Discussion 
Development of efficacious vaccines against potential agents of biological 
warfare, such as Y. pestis, requires the induction of rapid protection following 
immunization. The data described herein, demonstrates the potential for both CDN 
Vaccine and Combination Nanovaccine formulations to provide protection in as little as 
10 DPI (Figure 5.1 B and D). Though the survival conferred is variable between 
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experiments, combined overall protection provided by Combination Nanovaccine and 
CDN Vaccine was between 50-64%, which is still a significant improvement over 
unvaccinated animals who consistently succumb to challenge in as little as 3 days post-
challenge.  
Further analysis of the innate and humoral immune responses at these early time 
points may be better able to offer insight into the variability in protection observed. 
Though F1-V specific IgG (H+L) titers were similar across vaccinated groups at 9 DPI 
(Figure 5.1 A and C), it is possible that the titer measured is comprised of varying 
percentages of IgM and IgG subclasses, which may differentially contribute to 
neutralization and overall control of infection. Presence of a higher ratio of IgM to 
neutralizing IgG could be detrimental in overall protection conferred. 
Additionally, though we did not detect IL-1β, IL-4, IL-6, TNFα, or IFNγ in the 
serum at 4, 9, or 13 DPI (data not shown), it is possible that these cytokines are being 
upregulated locally in the draining lymph node or would be detectable at earlier time 
points (24-48 hours) following immunization. We did find evidence of systemic secretion 
of IL-12p40 in all vaccinated mice at 4 and 9 DPI, and in Combination Nanovaccine and 
saline mice at 13 DPI (Figure 5.3).  
IL-12p40, a component of IL-12p70 and IL-23, serves as a macrophage 
chemoattractant. IL-12p70 and IL-23 have been shown to promote IFNγ production by 
CD8 T cells in vivo and mediate inflammatory responses and macrophage accumulation 
in lung tissue, indicating a possible key role in control of pulmonary infections21. It is 
possible that the presence of IL-12p40 observed in the serum at 9 and 13 DPI could be 
contributing to larger production of local IFNγ, though none was detectable systemically. 
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Evaluation of cytokines in the draining lymph node at these same timepoints could allow 
further insight into the correlates of protection involved in this early protective response.  
Neutralization of TNFα and IFNγ significantly decreased the efficacy of 
Combination Nanovaccine immunization against challenge at 14 DPI (Figure 5.2 B).  
Consistent with these findings, previous work from Szaba et al. has shown that 
neutralization of TNFα and IFNγ, prior to challenge, significantly impairs survival 
induced by intranasal vaccination22. While neutralization of either TNFα or IFNγ reduced 
survival significantly, depletion of CD8+ T cells prior to challenge did not have as 
pronounced of an effect, suggesting that other cell types could be contributing to the 
production of these cytokines and overall protection22.  
In order to evaluate other cell types that may be contributing to protection and 
production of pro-inflammatory cytokines, it may be of interest to perform flow 
cytometry on draining lymph node cell populations at these early time points. 
Additionally, analysis of the bronchioalveolar lavage fluid between 10-14 DPI for 
presence of antigen-specific IgG could offer insight into the neutralizing capacity of 
antibodies induced by various vaccine formulations.  
Though highly variable, the induction of protective immunity in as little as 10 DPI 
is promising for application in biodefense or outbreak scenarios. Further research into the 
quality of the humoral immune response and possible contributions that trained innate 
immunity provide during early DPI by these vaccine candidates may provide insight into 
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CHAPTER 6.    DISCUSSION 
The development of high-quality novel vaccines is contingent not only upon their 
ability to be efficacious and provide protective immunity, but also on their potential for 
application. While many vaccines are capable of conferring protection in healthy 
individuals, general population protection still largely relies on herd immunity. The 
potential for a vaccine to induce protective immune responses in individuals who are 
typically “low-responders” or with immunological deficiencies would allow for a larger 
impact on global health. An ideal vaccine candidate should be efficacious in as few doses 
as possible, allowing for decreased cost associated with vaccination and better patient 
compliance. Additionally, an ideal vaccine formulation should be shelf-stable above 
refrigeration temperatures reducing the necessity for cold-chain storage.  
The use of combinatorial adjuvants, such as AS04 (MPLA and alum) or 
Combination Nanovaccine (polyanhydride nanoparticles and CDNs), may allow for the 
synergistic activation of many different aspects of the immune response. Antigen-specific 
humoral responses were induced by Combination Nanovaccine immunization, in as little 
as 10 DPI (Figure 5.1) and maintained through 218 DPI (Figure 3.3A and Figure 3.4). 
Characterization of the humoral response induced by immunization with Combination 
Nanovaccine or CDN Vaccine indicate no significant differences in overall magnitude of 
total antigen-specific IgG titer (Figure 3.2, 3.3, and 3.4), epitope specificity (Figure 3.7), 
presence of long-lived antibody-secreting cells (Figure 3.8), or isotype class-switching 
(Figure 3.5) between formulations, however, differences in protection were observed at 
varying challenge doses (Figure 3.2). This varying level of protection observed between 
the two formulations, at 14 DPI, indicates that the humoral immune response may not be 
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the sole correlate of protection against Yersinia pestis pulmonary infections.  
Further research into the quality of the humoral immune response at early time 
points, prior to 14 DPI, may provide further insight into the mechanisms of action 
conferring protection following immunization with Combination Nanovaccine 
formulation. Evaluation of germinal center formation, antigen-specific IgG in the 
bronchoalveolar fluid, and antibody-secreting cell presence in the spleen and lymph node 
at these early time points may highlight key differences between the early humoral 
immune response induced by each formulation. Additionally, the quality of the early 
humoral response in the draining lymph node, may be predictive of a durable, long-lived 
response.   
Significantly decreased efficacy of Combination Nanovaccine immunization was 
observed at 14 DPI following neutralization of TNFα and IFNγ 24 hours prior to Y. pestis 
challenge (Figure 5.2 B). This data indicates that these pro-inflammatory cytokines play a 
critical/contributing role in the acute protective immune response following 
immunization. Additional research into the cell types involved in production of TNFα 
and IFNγ could allow for better understanding of the cellular and innate immune 
responses rapidly induced following immunization.   
Immunization with Combination Nanovaccine formulation was also found to 
induce protective immunity at both early (14 DPI, Figure 4.1) and late (120 DPI, Figure 
4.2) time points in C57BL/6NHsdENV mice, which exhibited decreased overall humoral 
responses as compared to wild type (Figure 4.3) and may have had a mutation in the 
Dock2 gene. While Dock2 mutations are rare, many other disorders and deficiencies exist 
which exhibit lowered humoral responses to vaccination1–3. The potential for combined 
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adjuvants (CDNs and polyanhydride nanoparticles) in the Combination Nanovaccine 
formulation to overcome possible immunological deficiencies, makes it a promising 
vaccine candidate for use in the general population.  
Storage of polyanhydride-based nanovaccine formulation encapsulating PspA, for 
60 days at 25˚C, showed similar efficacy to more traditional cold-stored vaccine 
adjuvanted with alum (Figure 2.4). Removal of the soluble bolus from this formulation 
allowed for the storage of a dry powder formulation that was capable of maintaining 
efficacy and providing protection against lethal S. pneumoniae challenge, similar to those 
that were stored at freezer temperatures. This ability of the nanovaccine formulation to 
maintain efficacy following storage at temperatures above refrigeration, allows for a shift 
away from cold chain storage, currently recommended for all licensed vaccines4. Moving 
away from cold storage could be extremely beneficial in helping to facilitate easier 
dissemination of a vaccine, maintenance of vaccine efficacy, and decrease in cost 
associated with vaccine distribution and storage4–6.   
The use of an efficacious single-dose vaccine is beneficial, not only from the 
standpoint of patient compliance and cost, but also the humoral response. In humans, it 
has recently been suggested that repeat immunizations may push isotype class-switching 
to IgG4, which is a poor opsonin7. This switch in antibody production, following repeat 
boosters, could be detrimental against pathogens where the primary correlate of 
protection is opsonizing antibody. Additionally, patient compliance remains a large 
concern when considering vaccination strategies, as over two thirds of all cases of non-
compliance in children (age 19-35 months) are due to missed doses or mis-timed 
boosters8. Previous studies using F1-V have shown success in protection against lethal Y. 
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pestis challenge in macaques, guinea pigs, and mice, using a prime boost regimen9. It 
would be of interest, in future studies, to evaluate the potential for our Combination 
Nanovaccine to provide protection in a single-dose using these expanded animal models.  
Immunization with single-dose nanovaccine formulations against Y. pestis and S. 
pneumoniae, described herein, induced protective immunity against lethal challenge at 
both early (14 DPI) and late (180 DPI) timepoints following immunization, and 
maintained efficacy following room temperature shelf-storage. These characteristics, 
along with those previously described (i.e. tailored payload release kinetics10, protein 
shelf stability11, adjuvanticity12,13, biocompatibility14, low injection reactogenicity12, 
dose-sparing capabilities15), highlight the potential of polyanhydride nanoparticles as a 
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APPENDIX: DOCK2 MUTATION PRESENCE IN ENVIGO FACILITIES 
 
